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ABSTRACT   
Prematurity affects more than 10% of infants worldwide and is the main reason for neonatal 
mortality. Improvements in neonatal care have led to higher survival rates into adulthood. 
Adverse events during organogenesis and development, intra-or extrauterine, can increase the 
risk for chronic disease later in life. Developmental origins of health and disease is the 
epidemiologic research field linking early life events to related clinical phenotypes. 
In this thesis, we present 4 studies designed to follow up consequences of prematurity or low 
birth weight at term compared to term controls with normal birth weight in two different 
cohorts. The first cohort of children, studied at a mean age of 9.7 and again at 12.6 years 
(studies I-III), were born either very preterm (<32 weeks gestational age) or at term but small 
for gestational age. We studied kidney volume and function, the autonomous nervous system 
using heart rate variability and identified markers for insulin resistance. The second cohort of 
children, studied at a mean age of 7.7 years (study IV), were born extremely preterm (<28 
weeks gestational age). We measured kidney volume and function and divided the group into 
those who developed and those who did not developed nephrocalcinosis during the neonatal 
period. We also studied blood pressure at the time of their visit, including 24-h ambulatory 
blood pressure measurements.  
Kidney volume or function was not significantly different between the three groups in study 
I. In study IV we found that children born extremely premature had smaller kidneys then 
children born at term, in particular the right sided kidney volume was significantly smaller 
compared to controls. Preterm born girls had smaller kidneys than full-term born girls 
(controls) but preterm born boys were not different to controls. Among preterm born children 
without nephrocalcinosis girls, had smaller kidney volumes than boys. Kidney function was 
normal and not affected by kidney volume. 
Paper II showed signs for insulin resistance in very preterm born children and children born 
small for gestational age. Preterm born children presented signs for hepatic insulin resistance 
while small for gestational age born children had a decreased peripheral insulin sensitivity. 
Both, very preterm and full-term small for gestational age born children had a generalized 
depression of heart rate variability compared to controls indicating an impaired function of 
the autonomous nervous system (study III). Office blood pressure as well as 24-hour 
ambulatory blood pressure were in the normal range for children born very or extremely 
preterm as well as for children born small for gestational age at term. Circadian blood 
pressure regulation was adversely affected in 50% of children born extremely preterm 
illustrated by the absence of normal day-to-night dipping in 24-hour ambulatory blood 
pressure measurements (study IV).  
In conclusion, children born preterm or full-term but small for gestational age showed several 
morphological or functional changes at early school age. The detected changes are indicating 
a possible development towards impaired kidney function, hypertension and the metabolic 
syndrome.  
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1 INTRODUCTION 
An association between an environmental event very early in life (before or around birth) and 
an increment in disease susceptibility at a certain point or period later in life is the main 
paradigm of developmental origins of health and disease (DOHaD)1.The DOHaD research field 
is a rather young area of research. Initiated by British and Scandinavian researchers already in 
the 1930’s but then pioneered and brought to scientific acknowledgement by David Barker in 
the 1980’s2-4. DOHaD started with the discovery of an association between undernutrition 
during fetal development (maternal undernutrition) and the development of cardiovascular 
diseases and diabetes later in life2,5,6. But since than DOHaD research has expanded and found 
associations between adverse events occurring during a sensitive developmental phase early in 
life or before birth and outcomes or disease like asthma and allergy, immune and autoimmune 
diseases, cancer, depression, psychiatric, neurodevelopmental disorders and of course obesity, 
diabetes, hypertension and cardiovascular diseases7-11. The mechanisms behind the 
environmental effects on development and the clinical phenotype are largely explained by 
epigenetics which describes molecular mechanisms affecting gene expression patterns without 
alterations in DNA base sequence6. Epigenetic modification can happen via different 
mechanisms but the best studied so far are DNA methylation and histone modification12. 
Most of the research in this field was initially focusing on children born with low birth weight 
(LBW) in general assuming that the vulnerable period for development is limited to the fetal 
live. That was also reflected by the terminology and definition at that time where the research 
field was called “fetal” programming and later “fetal” origins of adult disease until first 2002 
the official name DOHaD was established by the main society. It was than accepted that the 
concept of DOHaD includes a huge span of environmental factors acting during different phases 
of developmental and potentially increasing the risk for later chronic diseases1,6. For the above 
reasons not much emphasis was put on the differentiation of the etiology of LBW, whether 
prematurity or IUGR being the cause. A distinction between these two different perinatal 
exposures seems reasonable as they display different etiologies. However, so far it appears that 
most of the long-term consequences are remarkably similar despite the different perinatal 
conditions (IUGR vs prematurity). The latency between the environmental adverse event and 
the possible subsequent manifestation of sequels is obviously very long which may complicate 
the appreciation of the relationship and delays diagnostics but also preventive and therapeutic 
measures. Development of early biomarkers as well as uncovering of differences in 
pathomechanisms and improvement of understanding of common trajectories for later disease 
risk is essential. 
With the research presented in this thesis we try to contribute to more detailed and specific 
clinically relevant evidence for this high-risk group and possibly improve knowledge and 
thereby open up for better and earlier prevention and management.  
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2 BACKGROUND 
2.1 PREMATURITY 
Gestational age describes the duration of gestation starting from the first day of the last 
menstruation and ending at birth and is expressed in completed weeks and days. By definition 
all infants being delivered prior to 37 weeks of gestation are premature. Prematurity can be sub 
divided into late preterm (32-36+6) very preterm (28-31+6) and extremely preterm (EPT, below 
28 weeks of gestation). Postterm is defined as delivery after 42 weeks of gestation13. Worldwide 
the rate of prematurity is around 15 million infants per year with the lowest rates in northern 
Europe (~5%) and the highest in sub-Saharan Africa (Malawi, 18%). Around 60% of all 
prematurity occurs in Asia and sub-Saharan Africa14. A combination of decline in stillbirth 
paralleled by lowering the threshold for preterm cesarean section delivery as well as an increase 
in late preterm birth has led to a rise in preterm birth in high-income countries15-17. According to 
the recent numbers of the Swedish National Quality register and the Swedish Board of Health 
and Welfare (SNQ, Socialstyrelsen) rates are 5.6% for infants born prior to completion of 37 
weeks of gestation, 1% for very preterm born (< 32weeks GA) and 0.3-0.4% for extremely 
preterm born children (< 28 weeks of GA) for the 120 000 children born per year18,19.  
2.1.1 Etiology of prematurity 
Despite a huge variety of accepted risk factors for spontaneous prematurity, no clear cause can 
be identified in the majority of cases20. Infection and inflammation, social stress and race and 
genetics can be used as the main pillars to explain spontaneous preterm birth21. Race, maternal 
education and maternal age as well as smoking during pregnancy or severe overweight or 
underweight increase the risk for preterm birth or low birth weight significantly22. Infections 
have been suspected as a cause for preterm birth for a long time and even though they are in 
most cases not clinically apparent they may contribute to as much as 25% of prematurity23,24. 
Maternal history of preterm delivery is a strong risk factor for recurrent preterm delivery which 
makes it likely that genetic factors or at least gene-environmental factors contribute to the 
timing of birth25. Also the mothers own prematurity increases the odds for delivering preterm26. 
Common maternal reasons for preterm delivery are preeclampsia, fetal distress and severe 
intrauterine growth retardation leading to medical induced preterm delivery. The variety in 
pathophysiological causes for prematurity results in each preterm born baby carrying his or her 
own individual profile of comorbidity. 
2.1.2 Survival and Mortality 
As the thresholds for viability were lowered over the last decades and the survival rates of 
extreme preterm born infants are improving the contribution of prematurity to mortality rates in 
children below five years consequently increased. Prematurity accounts for 35% of death 
among newborns and is globally with 17.9% the leading cause of deaths in children under the 
age of five years27. There is a great variance in survival and mortality rates not only between but 
also within countries. Infrastructural differences, attitudes towards decision making, quality of 
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care and socioeconomic circumstances may all lead to variations in mortality rates28,29. Child 
mortality in Sweden is among the lowest in the world (<5years: 2.9/1000)30. Also neonatal 
mortality in Sweden is rather low when compared internationally (SE: 1.5/1000; USA: 3.7/1000 
; UK: 2.6/1000) 18,30,31. 
2.1.3 Short and long-term morbidity of prematurity 
2.1.3.1 Respiratory distress syndrome 
Inversely related to gestational age with the most premature being mainly affected is the 
respiratory distress syndrome (RDS). Immature lungs with a deficiency of endogenous 
surfactant lead to alveolar instability and collapse32. This is the main reason for invasive or non-
invasive respiratory support in extremely preterm infants. Preventive and rescue strategies 
include antenatal steroids, exogenous surfactant application and continuous positive airway 
pressure.33,34.  
2.1.3.2 Bronchopulmonary dysplasia 
BPD is a complication in postnatal lung development mainly due to extreme prematurity, baro-
and volutrauma following mechanical ventilation and inflammation. It is defined by the need 
for supplemental oxygen after 36 weeks of postmenstrual age and can be further divided into 
mild, moderate and severe where the latter is defined by inspired oxygen > 30% or need for 
respiratory support 35,36. The incidence of BPD increases with decreasing gestational age at 
birth. Higher survival rates of more extreme preterm born infants have led to an increase of 
what sometimes is called the “new BPD” 37. in a recent survey the prevalence of BPD for 
infants born before 32 weeks of gestation in Sweden was 6%38. Mortality numbers for children 
suffering from severe BPD are between 10-20% during the first year of life. Pulmonary long-
term complications are reactive airway diseases and increased risk for severe pneumonia and 
bronchiolitis. Neurodevelopmental delay and growth failure are commonly seen in children 
suffering from severe BPD39,40. 
2.1.3.3 Germinal matrix and intraventricular hemorrhage  
The extreme premature infant is especially vulnerable to sudden changes in pressure and blood 
flow to the brain which may lead to bleedings often originating from a highly vascularized and 
cellular active area called the germinal matrix. These bleedings may extend into the ventricle 
system and potentially even into the parenchyma. Post hemorrhagic ventricle dilatation and 
hydrocephalus are potential complications. Severity of germinal matrix and intraventricular 
hemorrhage is most often graded by the Papile classification41. The prevalence of severe IVH 
(grade III+IV) is currently 3.4% in the Stockholm area for infants born before 32 weeks of 
gestation38. Neuro developmental outcome is strongly associated with intraventricular 
hemorrhage (IVH)42,43. 
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2.1.3.4 Periventricular leukomalacia /White matter injury 
Ischemia, hypoxia and inflammation to the brain are mainly affecting the periventricular white 
matter, predominantly in preterm newborns, resulting in persistent lesions which often are 
responsible for later cognitive, motor or sensory impairments44,45.  
2.1.3.5 Persistent ductus arteriosus  
The ductus arteriosus is an essential vascular communication in utero. Postnatally the duct 
closes itself but remains often open in preterm infants. Shunt direction, volume and duration of 
patency determine the relevance of the persistent ductus arteriosus (PDA). Significant left-to-
right shunting leads to pulmonary edema as well as to reduced systemic perfusion46,47. Opinions 
about when and if a PDA should be treated are varying significantly among institutions and 
clinicians. Treatment options can be pharmacological or surgical and interventional using 
transcatheter occlusion-technique48. 
2.1.3.6 Necrotizing enterocolitis  
Necrotizing enterocolitis (NEC) is a multifactorial severe gastrointestinal complication, almost 
exclusive in preterm, resulting in severe inflammation and tissue necrosis with the risk for 
perforation of the gastrointestinal tract. The pathomechanisms involved are decreased intestinal 
blood flow, mucosal injury and bacterial invasion but the complete etiology is still poorly 
understood. In case of severe NEC (1.3% in Stockholm) extensive surgery might be needed 
potentially leading to a short bowel syndrome, a rare but significant complication of NEC with 
an incidence of around 20%38,49. The mortality from NEC is high (20-30%) particularly for 
those in need for surgery50.  
2.1.3.7 Retinopathy of prematurity 
Retinopathy of prematurity (ROP) is the consequence of disturbed neurovascular development 
of the retina due to short gestational age and birth into a hyperoxic environment combined with 
inflammation. The abnormal neovascularization may lead to fibrosis, and ultimately retinal 
detachment resulting in blindness51. 
2.1.3.8 Neurodevelopmental delay  
Neurodevelopmental outcome is closely related to the spectrum of complications described 
above but also to prematurity itself50,52. The EXPRESS study group reported some kind of 
disability in 58% of extreme preterm born children in Sweden where severity of disability is 
inversely proportional to increasing gestational age53. Between 5-10 % of extremely preterm 
born infants, discharged alive from the neonatal care, developed cerebral palsy53. 
2.1.3.9 Autism spectrum disorder  
Autism spectrum disorders (ASD) can be described as a lifelong developmental disability 
mainly affecting social interaction, communication and often shows repetitive behavior. There 
is growing evidence that ASD is overrepresented in extreme preterm born children. In the EPT 
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born children it is suspected that ASD may be the consequence of abnormal brain development 
54,55. 
2.2 INTRA UTERINE GROWTH RETARDATION  
Intra uterine growth restriction (IUGR) describes a process where fetal growth fails to achieve 
the genetically determined growth potential of the individual due to one or multiple pathological 
factors56. The incidence of IUGR lies between 5-15% of all pregnancies in Europe and in the 
United States but can be as high as 55% in low income countries57. 
2.3 SMALL FOR GESTATIONAL AGE  
A newborn who weighs less than 2 standard deviations (SD) below the mean value for 
gestational age for a given population is described as small for gestational age (SGA). 
Alternatively, the World Health Organization (WHO) has chosen birthweight below the 10th 
percentile for identifying SGA58,59. Among children born preterm roughly 30% are also SGA38. 
Not all children born SGA have suffered from IUGR. The majority of children born SGA are 
constitutionally small and absolute healthy60. However, in this thesis and in studies I-III we 
mainly use the term SGA when referring to IUGR related LBW. 
2.4 RENAL DEVELOPMENT 
The development of the kidney is a complex process divided into three different phases where 
the first two phases (pronephros and mesonephros) are transient but leave their remains which 
are not only crucial for the further development of the kidneys but also play a role in the 
development of the genitals. The formation of the metanephros defines the final phase of renal 
development and starts at around 5 weeks of gestation and forms the permanent kidney61. The 
metanephros consists of the uretic bud epithelium as well as mesenchymal metanephric tissue 
components. The uretic bud epithelium differentiates into collecting duct and pelvis while the 
mesenchymal tissue develops into the proximal and distal loop as well as the glomerulus62. 
Nephrogenesis is a process of branching morphogenesis defining the final number of nephrons. 
In humans nephrogenesis is believed to continue up to 36 weeks of gestation leaving each 
individual with a finite nephron number endowment between 210 000 to 2.7 million nephrons63 
(figure 2). After that period kidney growth is mainly due to tubular growth and hypertrophy and 
if further nephrons are formed the number of abnormal glomeruli among those is high 64-68. 
However, glomeruli and tubular function continues to develop during the first months of life in 
term and also preterm born children which makes them particularly vulnerable to nephrotoxic 
drugs, severe infections or impaired perfusion69,70. 
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Figure 1. Duration of nephrogenesis in relation to gestational age (Modified after Tucker and Singh et 
al.13,71) 
 
2.5 KIDNEYS ROLE IN REGULATION OF ARTERIAL BLOOD PRESSURE 
The kidneys have a role in regulating body fluid homeostasis and thereby a long-lasting effect 
on blood pressure. Pressure diuresis and pressure natriuresis as well as the renin- angiotensin-
aldosteron system (RAAS) are slow but also fast acting mechanisms for blood pressure control. 
Reduced excretion capacity for sodium and water due to reduced filtration surface as seen in 
patients with nephron deficit can lead to hypertension65,72-74. Nephron number is reduced 
following low protein diet throughout pregnancy, utero placental insufficiency or preterm 
birth67,75. But apart from the “nephron number-Brenner hypothesis” other renal mechanisms can 
increase the risk for the development of hypertension. 
 
Figure 2. Congenital nephron deficit and development of hypertension and renal diseases (adapted 
from Brenner et al.72) 
Fetus 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
Preterm	<	37	weeks
Very	Preterm	<	32	weeks
Extremely	Preterm	<	28	weeks
Metanephrogenesis Week	36
PosttermTerm	birth	37-41	weeks
Week	5
Low nephron
number at birth
(PT/ IUGR) Reduced 
filtration surface 
area
Reduced filtered 
load
Sodium and fluid 
retention
Increasing ECF 
volume
Increasing 
arterial pressure
increasing 
glomerular 
capillary 
pressure
Increasing single 
nephron GFR
Glomerular 
hypertrophy
Glomerulo-
sclerosis
Further nephron 
loss
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Overactivity of the RAAS reflected by higher levels for angiotensin II, angiotensin converting 
enzyme and aldosterone have been described for children with low birth weight76,77. Vascular 
tone and small artery resistance regulations by the sympathetic nervous system are other 
possible contributing factors to renal hypertension and glomerular damage78. However, in the 
studies presented we focus on kidney volume which can be regarded as a proxy for nephron 
number67 and can be measured with ultrasound technique79-81. Subjects with low nephron 
number are having a 70% increased risk for kidney disease82 and due to the vicious cycle, 
described by Brenner et al., (Figure 2) a higher risk for the development of cardiovascular 
morbidities65,72,73,83. 
2.6 ELEVATED CHILDHOOD BLOOD PRESSURE 
Hypertension affects about 20% of all adults and is the main risk factor for cardiovascular 
morbidity worldwide84,85. Unlike for the adult patient blood pressure has to be adjusted for age, 
sex and height in children. In children blood pressure below the 90th percentile for systolic and 
diastolic pressure is classified as “normal” whereas above the 90th but below the 95th percentile 
blood pressure is classified as “elevated normal” blood pressure or pre-hypertension and above 
the 95th percentile it is classified as hypertension86,87. Currently the prevalence of established 
hypertension in children is about 4% and for pre-hypertension it is 10%88-90.It has been shown 
that childhood hypertension tracks into adulthood and is associated with an increased risk for 
atherosclerotic lesions leading to increased cardiovascular morbidity91-97. A raise of blood 
pressure in a young adult by only 5mmHg will increase the risk to die by stroke later in life with 
34%98.  
2.7 NEPHROCALCINOSIS  
Nephrocalcinosis (NC) is defined as the abnormal deposition of mainly calcium oxalate crystals 
into the renal parenchyma99. With an incidence varying between 7 and 41% among extremely 
preterm born infants (up to 64% in a single center100) NC is a rather common complication in 
this high risk group101-104. Immaturity of the kidneys with impaired excretory capacity and 
induced hypercalciuria by commonly used drugs during the neonatal period are suggested 
etiological explanations105-107. NC is reliably diagnosed with ultrasound technique108,109. 
Whether NC has an aggravating effect on kidney function in preterm born infants with possible 
reduced nephron number is currently under debate104,110-113. 
2.8 METABOLIC SYNDROME  
The metabolic syndrome (MetS) can be described as a cluster of pathologies potentially leading 
to cardiovascular diseases like atherosclerosis, hypertension myocardial infraction as well as to 
diabetes. By definition the MetS is present if some (at least 3) or all of the following symptoms 
are established: Insulin resistance, hyperinsulinemia, central obesity, high blood pressure, 
dyslipidemia (high triglycerides, low HDL, high LDL), procoagulant state (high plasma 
fibrinogen and plasminogen activator inhibitor 1), vascular abnormalities (increased albumin 
excretion in urine, endothelial dysfunction) and hyperuricemia114,115. According to a recent 
survey more than a third of all US adults met the criteria for the metabolic syndrome116.For non-
diabetic adult Europeans the prevalence is around 15%117. Among children the rise of childhood 
  8 
obesity had accompanied a significant increase in MetS as well. A study in obese children from 
five European countries using different definitions for the MetS showed a prevalence range 
between 16.4 to 35.7 % depending on the criteria used118. 
2.9 INSULIN RESISTANCE  
Insulin resistance (IR) is defined as the reduced biological capability of insulin to inhibit hepatic 
glucose production and facilitate glucose disposal119. IR is thought to be the central 
pathomechanism towards the MetS120. Hyperglycemia, obesity followed by inflammation and 
increasing free fatty acids (FFA) along with dyslipidemia and impaired endothelial function are 
steps ultimately resulting in the MetS.121,122. Hyperinsulinemia (indicative of insulin resistance) 
can also lead to hypertension by increasing plasma volume through promoting sodium 
reabsorption, increasing sympathetic activity as well as the proliferation of vascular smooth 
muscle cells123-125. IR can be either peripheral (or whole body) or central (hepatic). The 
pathomechanism for peripheral IR is impaired glucose uptake and consumption in muscle and 
fat tissue while hepatic or central IR results in unrestricted glucose production in the liver126,127. 
2.10 ROLE OF INSULIN-LIKE GROWTH FACTOR-1AND ITS BINDING PROTEINS 
Insulin-like growth factor-1 (IGF-1) is an amino acid single chain polypeptide with high 
similarity to insulin which is involved in growth, metabolism, differentiation and also 
angiogenesis128,129. IGF-1 is mainly produced by the liver due to growth hormone stimulation 
and applies its action via paracrine, autocrine and endocrine pathways130. Of the endocrine IGF-
1 approximately 95-99% is bound to binding proteins (IGFBPs) of which IGFBP-3 is the main 
binding protein regulating the action of IGF-1. IGFBP-1 is regarded as an important marker for 
glucose homeostasis131. Low levels of IGFBP-1 correlate with increased risk for the metabolic 
syndrome and type-2 diabetes mellitus(T2DM)132,133. Very recent research even suggests that 
IGFBP-1 has regenerative effect on beta cells and thereby reduces the risk for T2DM134,135 
2.11 NERVOUS CONTROL OF PERFUSION AND BLOOD PRESSURE 
The autonomic nervous system (ANS) is a central regulator collecting afferent and efferent 
neurons that link and synchronize the central nervous system with visceral effectors136. The 
neural control of the circulatory system depends on the interaction of the two major components 
of the ANS,  the sympathetic and parasympathetic arms of the ANS. The sympathetic branch of 
the ANS controls vascular tone, heart and kidneys and the adrenal medulla via barosensitive, 
thermosensitive and glucosensitive efferent neurons. The parasympathetic branch decreases 
heart frequency and contractility via fibers in the vagus nerves distributed mainly to the atria137-
139. The barosensitive efferents of the sympathetic nervous system are responsible for short term 
blood pressure fluctuations by affecting resistance arterioles or noradrenalin release but they 
have also a long-term effect on blood pressure regulation by influencing renin secretion, renal 
tubular sodium reabsorption and renal blood flow 140,141. 
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2.12 HEART RATE VARIABILITY  
ANS function can be assessed non-invasively by measuring heart rate variability (HRV). HRV 
represents the variation of time between consecutive heartbeats controlled by the two branches 
of the ANS and reflects the heart's ability to respond to different stimuli and circumstances. 
HRV has initially been use for observation and detection of fetuses in distress and led to the 
development of the cardiotocograph (CTG)142.The measurement of HRV can be used as a tool 
for examining cardiovascular autonomic control but is also giving information about activity 
related to respiration and thermoregulation. Abnormalities in HRV can be regarded as a proxy 
for impaired ANS function and thereby a predictor for cardiac and metabolic dysfunction in 
patients with preceded cardiac diseases but even among individuals free from cardio-vascular 
disease143-146. The measurement and illustration of HRV can be done in different ways. Most 
frequently time domain and frequency domain measurements are used147.  
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3 AIMS 
The overall objective for this thesis is to identify early markers for an increased cardiovascular, 
renal and metabolic risk for children born with LBW. 
 
• To investigate whether school children born with LBW have already impaired kidney 
volume and function (I+IV). 
• To investigate whether nephrocalcinosis is associated with long term kidney health in 
extremely pretem born infants (IV). 
• To evaluate early markers for insulin resistance (II).  
• To investigate whether the autonomous nervous system is affected by prematurity or 
LBW (III). 
• To investigate whether prematurity or LBW at term are equally associated with 
outcomes  investigated in study I-III. 
• To investigate if the above described suspected alterations have an effect on blood 
pressure (IV). 
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4 SUBJECTS AND METHODS 
4.1 STUDY POPULATION STUDIES I-III  
The retrospective follow-up studies I-III consists of children born between 1990-1993 who all 
belong to the same cohort. A total of 390 children born at the Karolinska University Hospital, 
Stockholm fulfilled the inclusion criteria and were eligible for the follow-up. Inclusion 
criteria were preterm birth before 32 weeks of GA, and birth at term but with a birth weight 
below the -2 SD according to the Swedish reference data for fetal growth148. Exclusion 
criteria were chromosomal anomalies, congenital infections, congenital anomalies of the 
urogenital tract or other life threatening congenital anomalies. Healthy children born at term 
with normal birth weight were selected from the delivery room records (Controls). One 
hundred thirty-three families were lost to follow up due to changed address. Of the remaining 
257 contacted families 105 accepted to participate in the study. 
The participating children were divided by their perinatal exposures. Thirty-nine children 
were born very preterm (<32 gestational weeks, Preterm), 29 children were born at term but 
were small for gestational age (SGA) and 37 children were born at term with appropriate 
weight for gestational age (Control). Children from the Preterm and SGA group were cared 
for at the neonatal intensive care unit (NICU) or maternity ward at the Karolinska University 
Hospital Stockholm, Sweden respectively. Children from the control group were healthy term 
born children matched for gender and date of birth, selected from the delivery room records 
from the same institution. Children not participating in the study were not different in their 
maternal, perinatal and neonatal characteristics. The children were initially investigated at an 
average age of 9.7 years and again at an average age of 12.6 years (Study I). Information 
about maternal anthropometrics, hypertension, diabetes, gestational diabetes, smoking habits, 
duration of lactation and any medical treatment or other significant disease during or before 
pregnancy were collected.  Perinatal and neonatal information included antenatal steroids, 
mode of delivery, Apgar scores, birth anthropometrics and relevant information towards 
neonatal complications and severity of illness were collected. 
 
 
Figure 3. Recruitment and study design (retrospective cohort study) 
 
Neonatal period years1 3 5 7 9 11 13
• Anthropometrics
• 24h	ECG
• Blood	pressure	
• Blood	and	
• urine	samples
• Anthropometrics
• Kidney	ultrasound
390 eligible	patient
Including	PT<32	w	GA,	
term	SGA	and	Controls
133 lost	to	follow	up
152 decline	participation
105 accepted
First	visit
Second	visit
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Table 1. Neonatal Characteristics for cohort 1 for the three different studies (I-III) for the three 
different groups: Children born preterm (<32 weeks of gestation) (Preterm), children born at term but 
with birth weight<-2 SD for gestational age (SGA), and children born at term with normal 
birthweight (Control). 
 
Values presented as means with (SD). Statistics were done with one-way Anova for comparison of all 
three groups. * denotes significant difference in comparison to control (P values <0.05). N: numbers, 
GA: Gestational age, w: Weeks, BW: Birth weight, g: grams, BL: Birth length. 
 
4.1.1 Methods Studies I-III 
All anthropometric measurements were performed by the same research nurse. Length, 
weight, head circumference, sitting height and abdominal circumference were measured. 
Children were wearing light indoor clothing for weight measurements. A wall mounted 
stadiometer was used for height measurements. Abdominal circumference was measured 
midway between the lower rib margin and the iliac crest using a normal measuring tape (only 
in 43 subjects (Preterm :7, SGA: 20, Control:16). Sex specific body mass index (BMI, kg/m2) 
was calculated. Body surface area was estimated by using the equation from Haycock149. 
4.1.1.1 Blood pressure recordings 
Office. blood pressure measurements were performed at a resting state after at least one-hour 
acclimatization to the environment. At least 3 measurements were taken using an automated , 
non-invasive oscillometric technique (Dinamapä, Criticon Inc., Tampa, Florida, USA)150 
with appropriate cuff size for age and size around the upper right arm. An average out of the 
three measurements was calculated for systolic, diastolic and mean arterial pressure.  
4.1.1.2 Blood and urine sampling 
Blood samples were obtained from 84 of the children (28 Preterm, 23 SGA and 33 Control) 
after placing a topical anesthetic cream containing 2.5% lidocaine and 2.5% prilocaine 
Preterm SGA Control
Study I II III I II III I II III
N 39 21 31 29 26 27 37 30 28
GA	(w)
26.6*	
(2.0)
26.4*	
(1.7)
26.7*	
(2.1)
39.3	
(1.4)
39.3	
(1.2)
39.3	
(1.4)
39.6	
(1.0)
39.6	
(1.0)
39.6	
(1.0)
BW	(g)
954*	
(203)
987.6*	
(217.7)
965*	
(202)
2436*	
(331)
2,467*	
(276.3)
2,441*	
(334)
3,485	
(502)
3,557	
(504)
3,503	
(515)
BL	(cm)
35.5*	
(2.9)
35.6*	
(3.4)
35.4*	
(2.9)
46.9*	
(2.4)
46.7*	
(2.1)
46.8*	
(2.3)
50.0	
(2.2)
50.2	
(2.2)
49.7	
(2.2)
Girls	(%) 56 42 48.4 55 57 59.3 65 63 64.3
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(EMLAâ; AstraZeneca, Sodertälje, Sweden). All blood and urine samples were analyzed at 
the Department of Clinical Pharmacology and Division of Clinical Chemistry at the 
Karolinska University Hospital Laboratory, Stockholm, Sweden. 
Blood and urine samples collected for study I were serum creatinine analyzed using the Jaffe 
method (Beckman Coulters instruments LX, Fullerton California, USA), serum cystatin-C 
(Dade Behring Nephelometer II (BNII)) urine albumin, immunoglobulin and alpha-1 
microglobulin using immunonephelometry method as well as urinary N-acetylglucosamine 
(U-NAG) analyzed with colorimetric method (Cobas Mira, Hoffmann-La Roche AG, Basel, 
Switzerland). The estimated glomerular filtration rate in ml/min/1.73m2 BSA (eGFR) was 
calculated with the Schwartz formula using serum creatinine 151. 
Blood samples for study II were blood glucose, measured by photometry ( HemoCue AB, 
Ängelholm, Sweden), serum-insulin measured by electrochemiluminescence immunoassay 
(Roche Diagnostics GmbH, Mannheim, Germany), HbA1c measured by cation exchange 
chromatography (MonoS column) with high-performance liquid chromatography (Roche 
Diagnostics, Basel, Switzerland), IGF-I and its binding protein (IGFBP-I) were measured 
with in-house radioimmunoassay’s (RIAs). Serum amyloid protein A (SAA) was measured 
by nephelometric technology (BN ProSPEC system, Siemens Healthcare, Erlangen 
Germany). High-sensitive C-reactive protein was measured by turbidimetry, infrared 
immunoassay rate method. Cholesterol and triglycerides were measured by enzymatic 
method and low density and high-density lipids (LDL, HDL) were measured by homogenous 
method (DXC800 (2020) Beckman Coulter Inc., Brea CA, USA). Apolipopreotein A1 and B 
were measured by turbidimetry (Beckman AB, Synchron LX, Beckman Coulter Inc., 
Diamond diagnostics, Holliston, MA, USA). 
4.1.1.3 Oral glucose tolerance test 
Following a 10-12 hour overnight fast a standardized oral glucose tolerance test (OGTT) was 
performed in all children giving 1.75g/kg body weight glucose (Orangedax; Custom 
laboratories, Baltimore, MD, USA) up to a maximum of 75g152 per individual. The above 
described blood samples were taken at 0 min as base line followed by blood samples for 
blood glucose, insulin and IGFBP-1 taken at 30 and 120 min from an intravenous catheter 
with heparin lock flush injection system (heplock, Baxter; One Baxter Parkway Deerfield, IL, 
USA).  
To estimate insulin resistance we used the homeostasis model assessment of insulin 
resistance (HOMA-IR= fasting plasma insulin x fasting plasma glucose/22.5)153 and the 
whole body insulin sensitivity index (WBISI= 10 000/square root of {(fasting glucose x 
fasting insulin) x (mean glucose x mean insulin during OGTT at 0,30,120min)}154. 
4.1.1.4 Heart rate variability (HRV), Study III 
A twenty-four-hour Holter electrocardiography (ECG) using an ambulatory recorder unit 
(Braemer DL700; Braemer, Burnsville, MN, USA) was obtained from 86 children. The 
Holter ECG system (Danica Holter Replay Unit; Danica Biomedical, Borlänge , Sweden) 
automatically analyzed cardiac conduction and rhythm disturbances as well as distinguished 
normal from non-normal QRS complexes. The values for consecutive RR intervals as well as 
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their corresponding classification code were exported to an ASCII text file.  For the 
frequency domain measurements of HRV, 5-minute data episodes were analyzes by custom-
made software155. Gaps in the time series due to non-normal RR intervals were filled with 
values calculated by linear interpolation between the adjacent normal RR interval. The 
software controlled for misclassified drop beats deviating more than three SD from the mean 
normal RR interval of each epoch. A minimum of 50% of the recordings had to be of 
acceptable accuracy in order to be included147. The frequency domain of the time series of 
RR intervals was analyzed with auto-regression method. Four different frequency bands of 
the total power spectrum were defined as by the standards of measurements147. Total power 
(Tot Pow, 0.0033-0.4 Hz (ms2)); very low frequency power (VLF Pow, 0.0033-0.04 Hz 
(ms2)); low frequency power (LF Pow, 0.04-0.15 Hz (ms2)); and high frequency power (HF 
pow, 0.15-0.40 Hz (ms2)) bands. For the time domain measurements, the mean of the SD of 
all normal RR intervals for all 5 min segments of each ECG recording (SDNN index) was 
calculated. 
4.1.1.5 Kidney ultrasound, Study I  
Kidney volume was measured in 86 of the children by using ultrasound technique. All 
measurements were performed by the same investigator using an Acuson 128xp system 
(Acuson, Mountain View, California, USA) with a 3.5-5MHZ linear transducer. Children 
were examined while in prone position lying on a pillow to compensate for lumbar lordosis if 
needed. Multiple images were taken from left and right kidney in longitudinal and transvers 
projections and the average from the largest measurements for length, width and thickness 
were entered in the formula for an ellipsoid (Figure 4 a, b) (volume= length x thickness x 
width x 0,523)156. 
                      a.)            
       
b.)    
Figure 4. a.: Illustration of ultrasound projections, b.: longitudinal and transversal projections of the 
right kidney of a 9 year old, male Control child. 
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4.1.2 Statistical analysis 
Data in all three studies are presented as numbers, percentage, mean values with 1 SD or 
confidence interval, or medians with quartiles and minimum and maximum values as 
indicated. For study I statistical analysis was computed with STATA software package, 
version 9, using the analysis of variance (ANOVA) command presenting regression 
coefficients for the specified model. Reported p-values from the ANOVA command were the 
p-values from the regression coefficients for the preterm and term SGA categories. We used 
ANOVA to analyze group difference in kidney function and volume. We considered group 
differences in renal volume and function of 10% as important. Therefore, we calculated the 
sample size to 30 in each group, with 80% power and a significance level of 0.05. For kidney 
volume comparison, we adjusted for gender, age, BSA and BMI. We used regression 
analyses to study possible associations between kidney volume and function and perinatal 
factors. Simple logistic regression was used for continuous variables and the chi-square test 
for binary variables. Variables with P<0.20 in simple regression were entered in stepwise 
forward regression. Those variables were: gestational age at birth, birth weight, gender, 
Apgar Score (10min), birth weight z-score, maternal hypertension during pregnancy, delivery 
mode, pre-and postnatal steroids, PDA and duration of continuous positive pressure support. 
For study II analysis were performed using Statistica StatSoft version 10.IGF-1 and IGFBP-1 
were not normally distributed and therefore log-transformed. Comparison between the groups 
were analyzed with ANOVA test followed by post hoc Fischer’s test for comparison between 
the separate groups. Pearson’s chi-square test was used for comparison of categorical data or 
percentages. Linear regression was performed using ponderal index (PI), weight and length 
SDS, mothers and father’s height, BMI, the percentage of IGFBP-1 change during OGTT (t0-
t120), the percentage change of insulin at 30 min, glucose and log transformed blood values. 
Analysis of covariance (ANCOVA) was used with BMI as a covariance variable and post hoc 
test was performed by planned comparison and Bonferroni correction. For study III analyses 
were computed in JMP software package, version 8.0.1 (SAS Institute, Cary, NY) using 
nonparametric Kruskal-Wallis test. Stepwise multiple regressions were performed to identify 
variables influencing HRV (gender, age at visit, BMI, maternal hypertension, maternal 
diabetes and prenatal steroid administration). The independent variables with F-to-enter=4 
were entered into logistic analysis model. For all studies a p-value of <0.05 was defined as 
significant. 
4.1.3 Informed consent and ethics 
The parents received oral and written information about the study protocol and the purpose of 
the study. All parents gave informed and signed consent prior to inclusion. The studies were 
approved by the Karolinska Institutet research ethics committee (I-III, Dnr 97-186). 
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Table 2. Characteristics at first visit for the three different studies (I-III) for the three different 
groups: Children born preterm (PT), small for gestational age (SGA) and with normal birth weight at 
term (control).  
 
Values presented as means with (SD) or percentage. Statistics were done with one-way Anova for 
comparison of all three groups. * denotes significant difference in comparison to control (P values 
<0.05).  
 
 
Table 3. Characteristics at second visit in children born preterm (PT), small for gestational age 
(SGA) and with normal birth weight at term (control) for study I.  
 Preterm  
(n=33)  
SGA  
(n=24) 
Control  
(n=29) 
Age, mean (SD), years 12.9 (0.3) 12.0 (0.3)* 12.7 (0.2) 
Females, n (%) 17 (51) 12 (50) 18 (62) 
Bodyweight, mean (SD), kg 47.5 (10.4)* 43.9 (10.6)* 52.2 (12.8) 
Height, mean (SD) cm 153.9 (9.4)* 152.9 (9.5)* 159.2 (8.9) 
Body mass index (BMI), mean (SD) kg/m2 20.1 (3.2) 18.3 (3.0) 20.6 (3.7) 
Body surface area (BSA), mean (SD) m2 1.42 (0.19) 1.35 (0.2)* 1.51 (0.22) 
Values presented as means with (SD)or percentage. Statistics were done with one-way Anova for 
comparison of all three groups. * denotes significant difference in comparison to control (P values 
<0.05).  
 
Preterm SGA Control
Study I II III I II III I II III
N 39 21 31 29 26 27 37 30 28
Age, (years)
9.6*	
(0.3)
9.5*	
(0.3)
9.6*	
(0.3)
9.8	
(0.3)
9.8					
(0.3)
9.8		
(03)
9.8						
(0.2)
9.8	
(0.2)
9.8	
(0.2)
Girls,	n	(%)
22	
(56)
9		
(42)
15	
(48.4)
16								
(55)
15	
(57)
16	
(59.3)
24	
(65)
19	
(63)
18	
(64.3)
Bodyweight, (kg)
32*	
(7.2)
29*	
(6.8)
31.8*			
(7.1)
32*					
(7.3)
30*	
(5.5)
31.8*			
(7.3)
38	
(9.0)
36	
(8.1)
37.9					
(8.1)
Height,	(cm)
134*	
(6.6)
137*				
(7.5)
134*				
(6.8)
137*	
(7.1)
136*	
(5.9)
137*				
(7.3)
142					
(7.6)
143	
(7.7)
142.6			
(7.5)
Body	mass	index
(kg/m2)
17.7	
(3.0)
16.4	
(2.4)
17.6	
(2.9)
16.8*		
(2.5)
15.9*			
(1.9)
16.8*			
(2.5)
18.5																
(3.2)
17.3	
(2.7
18.6	
(2.8)
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4.2 STUDY POPULATION STUDY IV 
A total of 213 infants born and cared for at the Karolinska University Hospital between 2008-
2011 with a gestational age below 28 weeks were eligible for inclusion in the study. Of those 
213 children 105 had a renal ultrasound investigation during their neonatal period performed 
by a pediatric radiologist to evaluate for nephrocalcinosis (NC) as by the clinical protocol. In 
37 cases the investigation result and/or the images were lost to follow up. Of the remaining 
68 investigated children 34 had been diagnosed with NC (NC+) where the other half showed 
no signs for NC (NC-). Of the initial 213 children 38 children died. For the group of 68 
children with a kidney ultrasound one child from the NC+ and 3 children form NC- group 
died (Figure 5.). Information on all relevant data reflecting on nephrotoxic substances as 
aminoglycosides, vancomycin, loop diuretics, thiazide diuretics, NSAID like Ibuprofen for 
treatment of PDA, antenatal and postnatal steroids were collected during the chart review 
process.  Duration of treatment was considered. Severity of illness as well as course of 
complication during the neonatal period was estimated by collecting data on Apgar Score, 
IUGR, RDS, BPD, acute kidney injury (AKI) defined and staged by the KDIGO guidelines, 
PDA receiving treatment, sepsis episodes (clinical and/or culture verified), NEC Bell stage II 
or more, surgical interventions, ROP grade III or higher (and or any plus disease) and IVH or 
parenchymal hemorrhage157-159. SGA was defined as a birth weight < mean −2 standard 
deviations (SDs) according to Swedish reference data for normal fetal growth148. There was 
no significant difference between the two groups of EPT born children with regards to the 
above listed treatments or complications. Three children from the NC+ group 5 children from 
the NC- group and none from the control group were SGA. None of the participating children 
had kidney or urinary tract malformations, congenital metabolic disorders, congenital 
abnormalities, genetic disorders or a positive family history for hyperoxaluria, cystinuria or 
any type of renal tubular acidosis.  
At school age families to the surviving 64 children with available ultrasound results from 
their neonatal period were contacted. In total 41/64 families agreed to participate and 20 
children in the NC+ group and 21 children in the NC- group could be investigated (Figure 5). 
All renal ultrasound images from the neonatal period were reviewed by a single senior 
pediatric radiologist. Diagnosis was confirmed in 39 out of 41 cases. In each group 
(NC+/NC-) one patient was misdiagnosed and moved to the opposite group. The degree of 
nephrocalcinosis was sub classified into mild, moderate and severe during the review process. 
Of the 20 children 12 had mild, 5 had moderate and 3 had severe NC. The 23/64 non-
participants were not different to the study population with regards to gestational age, birth 
anthropometrics or severity of illness.  
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Figure 5. Recruitment flow chart for study IV 
 
 
Table 4. Neonatal characteristics for the three groups: Extremely preterm infants born <28 weeks 
gestational age (EPT) with nephrocalcinos (NC+) or without nephrocalcinosis (NC-) during the 
neonatal period and full-term controls (Control 
 
EPT NC+ 
(n = 20) 
EPT NC- 
(n = 21) 
Control 
(n=19) 
P, ANOVA / 
NC+ vs NC- 
Males n (%) 9 (45) 13 (61.9) 10 (52.6) 0.55 / 0.27 
Gestational age, mean (SD) in weeks 25.5 (1.2) 25.9 (1.3) 39.7 (1.6) <0.0001 / 0.22 
Birth weight, mean (SD) in g 755 (124) 841 (202) 3586 (477) <0.0001 / 0.10 
Birth weight, SDS, (SD) -0.93 (0.78) -0.87 (1.22) 0.19 (0.93) 0.0012 / 0.85 
Birth length, mean (SD) in cm 32.4 (1.8) 33.6 (2.6) 50.4 (1.9) <0.0001 / 0.08 
Head circumference, mean (SD) in cm 23.3 (1.3) 24.0 (1.8) 34.6 (1.4) <0.0001 / 0.12 
SGA, n (%) 3 (15%) 5 (24%) 0 (0) 0.028 / 0.47 
Apgar score at 5 min, mean (SD) 6.7 (2.9) 7.4 (2.1) 10 (0.0) 0.0007 / 0.36 
Apgar score at 10 min, mean (SD) 8.4 (1.7) 8.7 (1.9) 10 (0.0) 0.022 / 0.59 
Values are presented as numbers and percent (n, (%)). Statistics were done with one-way Anova for 
comparison of all three groups followed by post-hoc students t-test for continuous variables and 
Pearson’s Chi-square test for categorical data when compared NC+ with NC-. P values <0.05 were 
considered significant. 
 
 
 
213 PT	<	28w	GA
68
renal	US
107
no	renal	US
34 NC+ 34 NC-
20 NC+ 21 NC-
1 deceased
13 declined
3 deceased
10 declined
105	
renal	US	performed
37	
US	results	not	traceable	
19
healthy	term	AGA
as	control	group
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4.2.1 Methods Study IV 
Basic anthropometric measurements were identical to those for study I-III. In addition, lean 
body mass in kg was measured using DEXA technique by subtracting the percentage body fat 
from the total body weight. We were able to use this information as this study is part of a 
larger project were body composition measurements are of importance. DEXA results were 
available for 12, 16 and 17 children from the NC+, NC-  and control group respectively.  
4.2.1.1 Blood pressure recordings 
Office blood pressure was measured using oscillometric technique (Dinamap Carescape 
V100, GE Healthcare, Illinois, USA) following standardized recommendations87. We also 
monitored 24-hour ambulatory blood pressure (ABPM) using a SPACELABS 90217A 
device (SpaceLabs Medical Inc., Redmond, Washington, USA) in children born preterm but 
not in controls where normative reference data were used instead86. Day-to-night BP decline 
was calculated by the equation (sleep BPsystolic-awake BPsystolic/awake BPsystolic) x100. 
“Extreme dipper” was defined as BP decline more than 20%, normal decline from day to 
night BP was defined as 10-20%, decline less than 10% was defined as “non-dipper” and an 
increase in sleep BP was defined as “riser”160. 
 
Figure 6. 24hour ambulatory blood pressure monitoring (ABPM) from a patient (NC+) illustrating 
normal (>10%) day-to-night decrease of systolic and diastolic blood pressure.  
 
4.2.1.2 Blood and urine sampling 
Blood samples were collected in 54 patients (17 NC+, 20 NC-, 17 controls). Blood samples 
were taken after placing a topical anesthetic cream containing 2.5% lidocaine and 2.5% 
prilocaine (EMLA; Astra Zeneca, Södertälje, Sweden). Urine sample were collected in 58 
patients (19 NC+, 20 NC -, 19 controls). Blood samples were investigated for plasma sodium, 
potassium using potentiometry with ion selective electrodes (Cobas 8000, Cobas C ISE2, 
Roche, Basel Switzerland), calcium, phosphate, alkaline phosphatase, creatinine and urea 
23:00 07:00
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using photometric technique and cystatine-C using immunochemical and turbodimetric 
method (Cobas 8000 Cobas CC 701 Roche, Basel Switzerland). Urine samples were 
investigated for sodium and potassium measured using potentiometry with ion selective 
electrodes (Cobas 8000, Cobas C ISE2, Roche, Basel Switzerland). Phosphate, calcium and 
magnesium were measured using photometric technique (Cobas 8000 Cobas CC 701 Roche, 
Basel Switzerland) and albumin was measured using immunochemical and turbodimetric 
method (Cobas 8000 Cobas CC 701 Roche, Basel Switzerland). Protein HC and 
immunoglobulin G was measured by immunochemical and nephelometric method (BN Pro 
Spec, Siemens Healthcare, Erlangen, Germany). For the estimation of GFR we used the 
simplified Schwartz formula as well as the cystatin-C based CAPA formula described 
elsewere151,161.  
4.2.1.3 Kidney ultrasound 
Kidney volume in study IV was measured in the same way as in study I. Again all 
measurements were performed by the same investigator. A newer, different ultrasound 
system was used (Philips EPIQ 7G with SW1.5.2 software (Philips Ultrasound, Inc. 22100 
Bothell Everett Hwy Bothell, WA 98021-8431, USA) and a 2-9 MHZ frequency (Phillips 
C9-2) curved transducer was used. All investigations for the neonatal period were performed 
by different specialists in pediatric radiology using a Siemens S 2000 system with a 6C2 
curved transducer (Siemens, Erlangen, Germany). As mentioned above, all renal ultrasound 
images from the neonatal period were reviewed by a single senior consultant in pediatric 
radiology in 2018. 
Table 5. Characteristics at visit for the three groups: Extremely preterm infants born <28 weeks 
gestational age (EPT) with nephrocalcinos (NC+) or without nephrocalcinosis (NC-) during the 
neonatal period and full-term controls. 
 
PT NC+ 
(n = 20) 
PT NC- 
(n = 21) 
Control 
(n = 19) 
ANOVA/ 
NC+ vs NC- 
Age at visit, mean (SD) in years 7.8 (1.0) 7.4 (1.1) 8.1 (1.2) 0.14/0.2 
Body weight, mean (SD) in g 22.5 (5.8) 22.3 (5.4) 26.7 (4.0) 0.02 /0.9 
Body weight SDS (SD) -1.26 (1.5) -0.87(1.3) -0.02 (0.7) 0.01 /0.4 
Body height, mean (SD) in cm 120 (7.6) 121 (8.3) 129 (8.6) 0.0005 /0.5 
Body Height SDS (SD) -1.2 (1.2) -0.5 (0.9) 0.2 (0.7) 0.0001/0.03 
Head circumference, mean (SD) in cm 51.1 (1.6) 51.8 (2.2) 53.4 (1.6) 0.0009/0.2 
Waist circumference, mean (SD) in cm 58.0 (7.4) 55.5 (5.5) 57.7 (3.3) 0.3/0.2 
Waist-to-height ratio, mean (SD)  0.48 (0.05) 0.45 (0.03) 0.44 (0.02) 0.005/0.04 
BMI, mean (SD) in kg/m2 15.5 (2.4) 14.9 (1.8) 15.7 (1.2) 0.4/0.4 
BMI SDS (SD) -0.7 (1.4) -0.9 (1.6) -0.2 (0.8) 0.26/0.6 
BSA, mean (SD) in m2 0.86 (0.13) 0.86 (0.12) 0.98 (0.11) 0.003/0.9 
Lean body mass (12/16/17) in kg 15.8 (2.7) 15.6 (3.0) 19.6 (3.5) 0.001/0.8 
Values are presented as numbers and percent (n (%)). Statistics were done with one-way Anova for 
comparison of all three groups followed by post-hoc students t-test for continuous variables when 
compared  NC+ with NC-. P values <0.05 were considered significant. 
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4.2.2 Statistical analysis 
For descriptive statistics, continuous variables were presented with mean and standard 
deviation (SD). Continuous variables, approximately normally distributed were analyzed with 
respect to the three defined groups, using Analysis of variance (ANOVA). In order to adjust 
for continuous prognostic variables covariance analysis was used (ANCOVA). Stepwise 
regression analysis was used to examine the impact of a set of prognostic variables.  Non-
normal continuous variables were analyzed with Kruskal Wallis test. Dichotomous variables 
were analyzed with cross tables and Pearson’s Chi-square test. As an additional analyses the 
kidney volume was analyzed with a mixed effects model including right and left volume in 
the same analysis. A hierarchical model with the child as the main unit was set up, taking into 
consideration the correlation between right and left side, with the unstructured covariance 
structure unstructured (UN). In all statistical analyses the relevant assumptions were checked. 
A p value <0.05 was considered significant. 
4.2.3 Informed consent and ethics 
The parents received oral and written information about the study protocol and the purpose of 
the study. All parents gave informed and signed consent prior to inclusion. The study was 
approved by the Karolinska Institutet research ethics committee (IV, Dnr 2016/1258-31). 
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5 RESULTS 
5.1 STUDY I 
Renal volume and function in school-age children born preterm or small for gestational 
age. 
Anthropometrics 
At first visit weight, height and BSA were significant lower in PT and SGA group in 
comparison to controls. BMI was lower in SGA group but not for the PT group. At second 
visit weight and height were still lower among children in the PT and SGA group than in 
controls but BMI was lower in SGA and not in the PT group. BSA was lower in the SGA 
group at second visit (Table 2,3). At first visit age in the PT group was lower in comparison 
to the controls and SGA group (p<0,05). At second visit due to the slightly different 
composition of study individuals out of the same groups, age was significant lower in the 
SGA group but not in the PT group in comparison to controls (Table 3). 
Blood pressure  
Systolic and diastolic blood pressure measured at rest, orthostatic test and following a 
mathematical stress test was not different between the three groups. The detailed results for 
blood pressure measurements reflecting on the cohort investigated for study I-III are 
published by our research group but are not part of this thesis162. 
Kidney volume  
Unadjusted kidney volume was lower in the group of children born preterm in comparison to 
controls (means (SD) 162ml (31) vs 182ml (47), p=0,035). The difference between the two 
groups remained significant when adjusting for gender, age and BMI (p=0,046). 
Children born at term but small for gestational age had also a lower total kidney volume than 
controls but the difference did not reach significance (163ml (26) vs 182ml (47), p= 0,073). 
After adjustment for BSA, age and gender the difference between PT and controls diminished 
(20 ml to 7,5 ml) and was no longer significant. The difference in total kidney volume 
between SGA and controls remained insignificant after adjustments. Adjusted left and right 
kidney volume separately were not significant different among the groups. 
Correlation analysis showed that birth weight correlated to total renal volume (r=0,23, 
p=0,03) but not to gestational age (r=0.33, p=0.06).For the preterm group birth length 
correlated to total kidney volume (r=0,36, p=0,4). 
Kidney function  
Estimation of renal function with serum creatinine using the Schwartz formula was possible 
in 84 subjects (PT=28, SGA=23, controls=33). There was no significant difference in eGFR 
between the three groups. Serum concentrations for creatinine and cystatin C did not differ 
between the three groups. The urinary protein excretion calculated as ratio to urinary 
creatinine were not different between the groups (Table 7).  
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Table 6. Unadjusted kidney volume in healthy children born preterm (PT), small for gestational age 
(SGA) and with normal birth weight at term (Control). Values are given in means (SD) 
 PT (n= 33) SGA (n= 24) Control (n=29) 
Total kidney volume (ml) 162* (31) 163 (26) 182 (47) 
Right kidney volume (ml) 82.4 78.4 91.1 
Left kidney volume (ml) 79.5 84.8 90.4 
Results from one-way ANOVA ,*denotes significant difference (p< 0.05) compared to controls 
 
 
 
Table 7. Kidney function parameters, urinary protein excretion expressed as ratios to urinary 
creatinine in healthy children born preterm (PT), small for gestational age (SGA) and with normal 
birth weight at term (Control). All values given as means (SD) 
 PT (n=28) SGA (n=23) Control (n=33) 
Serum- creatinine, mmol/l 77.1 (1.8) 77.9 (1.9) 81.6 (1.6) 
Serume cystatin-C, mg/l 0.91 (0.03) 0.88 (0.03) 0.83 (0.03) 
eGFR ml/min/1.73m2 body surface area 89.6 (13.5) 88.8 (12.3) 88.3 (10.7) 
 (n=12) (n=22) (n=16) 
Urine albumin mg/mmol 0.6 (0.4) 0.8 (0.7) 0.7 (1.0) 
Urine IgG mg/mmol 0.2 (0.1) 0.3 (0.2) 0.4 (0.4) 
Urine A1M mg/mmol 0.7 (0.7) 0.6 (0.6) 0.6 (0.7) 
Urine NAG nkat/mmol 4.7 (3.4) 3.2 (1.5) 3.7 (3.5) 
Results from one-way ANOVA. Urine IgG: urine immunoglobulin, Urine A1M: urin-alpha-1-
microglobulin, Urine NAG: urine-N-acetylglucosamin 
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5.2 STUDY II 
Differences in insulin resistance markers between children born small for gestational 
age or born preterm appropriate for gestational age. 
We investigated 84 children from the same cohort as in study I but individuals participating 
in this study are not completely identical to those investigated in study I. 
Anthropometrics 
Children born preterm were younger at study time than children born SGA or control (Table 
2). Both groups of children with low birth weight (preterm and SGA group) were 
significantly lighter and shorter and  standard deviation score (SDS) for weight and height 
were also significant lower in comparison to controls (p£0.02 for all)). Head circumference at 
time of investigation was still significantly lower in children born preterm or SGA (p= 0.004, 
<0.001 respectively) and BMI only in term children born SGA versus control. Among the 
SGA children only girls had significantly lower BMI but not boys (p= 0.001 vs 0.89). 
Children born preterm had no different BMI than controls which remained unchanged for 
boys and girls. BMI SDS was only significant lower for the SGA group but not for preterm 
(p= 0.003; 0.22 respectively) in comparison to controls. 
 
Insulin resistance 
Results for the OGTT showed adequate and normal values for all three groups without any 
significant difference between the groups. HBA1c levels were normal for all groups with no 
significant difference between the groups (p=0,13). Unadjusted insulin resistance indexes 
HOMA-IR and WIBSI as well as baseline values for insulin, IGF-1 and its binding protein 
were not different between the groups of children with different perinatal exposure (Table 8). 
After adjustment for BMI HOMA-IR was significantly higher and WIBSI significantly lower 
in the group of children born SGA compared to controls. Fasting and stimulated Insulin 
levels at 30 minutes in the SGA group were significantly higher in comparison with controls 
A difference not seen for preterm born children (Table 9). 
During the OGTT the decrease of IGFBP-1, following glucose stimulation, was significantly 
slower for the children born preterm compared to controls and children born SGA at term (p= 
0.045; 0.007 respectively). 
Inflammatory markers, hsCRP and SAA, were not different among the children of the three 
groups (p= 0.3, p=0.46 respectively). The lipoproteins, cholesterol, HDL and LDL and their 
ratios (cholesterol/HDL, LDL/HDL) as well as triglycerides, Apo A1 and Apo B did not 
differ significantly between the Preterm, SGA and control group. 
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Table 8. Unadjusted results for OGTT at fasting level (t0), at 30 min (t30) and at 120 min (t120) for 
the group of preterm born children (PT), term born but SGA (SGA)and term with adequate birth 
weight (Control). 
 PT 
(n=21) 
SGA 
(n=26) 
Control 
(n=30) 
P-value 
 
HbA1c, %,                    
t0 
4.6 (4.5-4.7 4.4 (4.3-4.5) 4.4 (4.3-4.5) NS 
B-glucose, mmol ⁄L      
t0 
4.4 (4.1–4.6) 4.4* (4.2–4.7) 4.1 (3.9–4.3) NS                        
SGA vs C: 0.042 
B-glucose, mmol ⁄ L     
t30 
8.0* (7.4–8.7) 7.8 (7.2–8.3) 7.2 (6.7–7.7) NS                     
PT vs C: 0.039 
B-glucose, mmol ⁄ L    
t120 
6.0 (5.5–6.4) 5.8 (5.4–6.3) 5.8 (5.5–6.2) NS 
B-glucose increase,   
t0–t30 
3.7 (3.0–4.3) 3.3 (2.7–3.9) 3.1 (2.5–3.6) NS 
S-Insulin mU⁄ L         
t0 
4.3 (3.3–5.5) 5.3 (4.3–6.7) 4.8 (3.9–5.9) NS 
S-Insulin mU⁄ L         
t30 
49 (37–63) 52 (40–66) 41 (32–52) NS 
S-Insulin mU⁄ L         
t120 
27 (20–36) 30 (23–40) 29 (22–38) NS 
Insulin ratio,              
t30 ⁄ t0 
11.4 (9 -14.4) 9.7 (7.6–12.4) 8.6 (6.9–10.6) NS 
S-IGFBP-1 lg⁄ L        
t0 
45 (34–60) 43 (35–54) 44 (36–54) NS 
S-IGFBP-1 lg⁄ L        
t30 
46 (34–64) 42 (34–52) 40 (32–50) NS 
S-IGFBP-1  lg⁄ L       
t120 
23 (16–31) 18 (14–23) 19 (15–25) NS 
% IGFBP-1,              
t120 ⁄ t0 
52 (47–58) 42 (37–47) 45 (40–49) 0.023                 
PT vs C: 0.045 
PT vs SGA 0.007 
S-IGF-1 lg⁄ L               
t0 
229             
(194–270) 
198               
(170–231) 
207                
(180–238) 
NS 
HOMA–IR 0.82         
(0.61–1.11) 
1.05            
(0.86–1.28) 
0.87          
(0.68–1.13) 
NS 
WBISI 2445       
(2074–2815) 
2115        
(1903–2326) 
2386       
 (2090–2683) 
NS 
p-values according to ANOVA followed by post-hoc Fisher´s test. Values are in mean (95% 
CI)(geometric means for hormone values and HOMA-IR) or %. 
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Table 9.  Results for OGTT at fasting level (t0), at 30 min (t30) and at 120 min (t120) adjusted for 
BMI for the group of preterm born children (PT), term born but SGA (SGA)and term with adequate 
birth weight (Control). 
 
PT  
(n=21) 
SGA  
(n=26) 
Control  
(n=30) 
P-value 
ANCOVA 
PT vs C 
SGA vs C 
PT vs SGA 
 
S-Insulin, mU⁄ L t0 
 
4.3 (3.5–5.3) 
 
6.0 (4.9–7.4) 
 
 
4.3 (3.5–5.1) 
 
0.025     
1.0          
0.029           
0.045 
 
S-Insulin, mU⁄ L t30 
 
49 (39–62) 58 (46–73) 37 (30–46) 
0.020    
0.16 
 0.012 
0.62 
 
S-IGFBP-1, lg ⁄ L, t0 
 
45 (37–54) 38 (31–46) 50 (42–59) 
0.11 
0.8 
0.076 
0.46 
HOMA–IR  
0.83         
 (0.66–1.05) 
1.19          
(0.96–1.48) 
0.78         
 (0.64–0.95) 
0.016 
1.0  
0.013 
0.051 
WBISI   
2429        
(2156-2702) 
1971        
(1713-2229) 
2526       
(2282-2770) 
0.008 
1.0           
0.007 
0.035 
p-values are according to ANCOVA test with BMI as co-variance variable, followed by post-hoc 
planned comparison and Bonferroni correlation. Values are in mean (95% CI) (geometric means for 
hormone values and HOMA-IR). BMI: body mass index, IGFBP-1 Insulin like growth factor binding 
protein-1, HOMA-IR: Homeostasis model assessment-insulin resistance, WBISI: Whole-body insulin 
sensitivity index. 
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5.3 STUDY III 
Decreased heart rate variability in children born with low birth weight 
Maternal data 
Prevalence of maternal smoking, gestational diabetes, gestational hypertension or history of 
hypertension were not different between the three groups. 
Anthropometrics at visit 
At visit, children born preterm were younger than children born SGA or control AGA (Table 
2). Children from the preterm and SGA group were significantly lighter and shorter than 
controls. BMI was only lower in the SGA group compared to controls (Table 2). 
Heart rate variability 
Frequency domain parameters for the groups born preterm and SGA were significantly lower 
in comparison to healthy term born children (controls) at visit (Table). The ratio between low 
frequency and high frequency power (LF/HF ratio) was not different between the three 
groups. Time domain parameters as Mean RR and SDNN were also significant lower for 
preterm and SGA born children. 
 
Table 10. Results for heart rate variability parameters in time and frequency domains for children 
born preterm (PT), born at term but small for gestational age (SGA) and children born at term with 
normal birth weight (Controls). Values are given as means and 95% confidence intervals. 
 Preterm 
(n=31) 
SGA 
(n=27) 
Control 
(n= 28) 
P value 
Tot Pow (ms2) 4.405*           
(3.514–5.297) 
3.965*          
(3.030–4.901) 
6.344            
(5.109–7.579) 
0.008 
HF Pow (ms2) 1.815*           
(1.299–2.331) 
1.363*             
(994–1.732) 
2.934            
(2.099–3.769) 
0.01 
VLF Pow (ms2) 1.160*               
(980–1.340) 
1.203*             
(884–1.522) 
1.535             
(1.298–1.771) 
0.02 
LF Pow (ms2) 1.429*           
(1.132–1.744) 
1.399*             
(1.036–1.738) 
1.875            
(1.509–2.074) 
0.04 
LF/HF ratio 1.4 (1.2–1.6) 1.6 (1.4–1.8) 1.4 (1.1–1.7) 0.09 
Mean RR (ms) 701* (670–732) 684* (648–720) 739 (711–767) 0.02 
SDNN (ms) 74* (67–81) 71* (63–79) 89 (80–98) 0.006 
Denotes p < 0.05 in comparison to controls according to Kruskal-Wallis test. Tot Pow: Total power, 
HF Pow: high frequency power, VLF Pow: very low frequency power, LF Pow: low frequency power, 
LF/HF ratio: low frequency/high frequency ratio, Mean RR: mean of R wave to R wave variation, 
SDNN: the mean of the SD of all normal RR intervals for all 5-min segments. 
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5.4 STUDY IV 
Nephrocalcinosis in extremely preterm born infants as a risk factor for impaired renal 
size and function at early school age. 
Maternal data 
Prevalence of maternal smoking, gestational diabetes, gestational hypertension or history of 
hypertension were not different between the three groups. 
Anthropometrics at visit 
Children in the control group were insignificantly older than both groups of preterm born 
children but significantly heaver, taller and with a larger head circumference. However, BMI 
and waist circumference was not different between the three groups. Mean waist 
circumference and waist-to-height ratio was highest in the EPT NC+ group (Table 11). 
 
Table 11. Characteristics at visit for the three groups: Extremely preterm infants born <28 weeks 
gestational age (EPT) with nephrocalcinosis (NC+) or without nephrocalcinosis (NC-) during the 
neonatal period and full-term controls.  
 EPT + NC 
(n = 20) 
EPT –NC 
(n = 21) 
Control 
(n = 19) 
P, ANOVA / 
NC+ vs NC- 
Age,  mean  (SD) in years 7.8 (1.0) 7.4 (1.1) 8.1 (1.2) 0.14 / 0.2 
Body weight, mean (SD) in g 22.5 (5.8) 22.3 (5.4) 26.7 (4.0) 0.016 / 0.89 
Body weight SDS -1.26 (1.5) -0.87(1.3) -0.02 (0.7) 0.01 / 0.39 
Body height, mean (SD) in cm 120 (7.6) 121 (8.3) 129 (8.6) 0.0005 / 0.5 
Body Height SDS -1.2 (1.2) -0.5 (0.9) 0.2 (0.7) 0.0001/ 0.03 
Head circumference, mean 
(SD) in cm 
51.1 (1.6) 51.8 (2.2) 53.4 (1.6) 0.0009 / 0.25 
Waist circumference, mean 
(SD) in cm 
58.0 (7.4) 55.5 (5.5) 57.7 (3.3) 0.34 / 0.24 
Waist-to-height ratio, mean 
(SD)  
0.48 (0.05) 0.45 (0.03) 0.44 (0.02) 0.005 / 0.04 
BMI, mean (SD) in kg/m2 15.5 (2.4) 14.9 (1.8) 15.7 (1.2) 0.44 / 0.45 
BMI SDS  -0.7 (1.4) -0.9 (1.6) -0.2 (0.8) 0.26 / 0.65 
BSA, mean (SD) in m2 0.86 (0.13) 0.86 (0.12) 0.98 (0.11) 0.003 / 0.9 
Values are presented as means and standard deviation (SD). Statistics were done with one-way Anova 
for comparison of all three groups followed by post-hoc students t-test for continuous variables when 
compared NC+ with NC-. P values <0.05 were considered significant 
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Kidney volume 
All kidney volumes were adjusted for BSA following linear regression analysis. Total kidney 
volume in girls was significantly lower for both preterm groups in comparison to controls 
(Table 12). In boys, no difference could be seen between preterm groups and controls. Using 
the mixed effects model analysis where BSA, gender and each kidney side were included, the 
direct comparison between boys and girls showed a significant lower kidney volume for girls 
in both preterm groups in comparison to the control group (p=0.0048; p=0.016 respectively). 
Both gender taken together total kidney volume between preterm and controls reached only 
borderline significance (p=0.056). Right sided kidney volume was significantly lower in NC+ 
and NC- group separately and together compared to controls. Left kidney size was not 
different between the three groups. Right sided kidney length was significantly shorter for 
NC+ and NC- group when compared to controls. Left sided kidney length was not different 
between the three groups. In a mixed effect model including right and left volume for all 
groups we found a trend towards lower right sided kidney volume for all groups including 
controls (p=0.055). 
An alternative way to adjust for body size and volume has recently been described and has 
been used in comparable studies. A simple quote was used to adjust kidney volumes for BSA 
by dividing measured volume by BSA (KV/BSA)163. When using this adjustment, the NC+ 
group had significantly lower total kidney volume than controls but not NC- group of preterm 
born children (Table 13). Both preterm groups taken together had significant lower kidney 
volume in comparison to controls (Table 13). When looked at side specific kidney volumes 
by using (KV/BSA) right sided kidney volume was significantly lower for NC+ preterm born 
children while for the left side the NC- group had lower kidney volume (Table 13). When we 
directly compared the NC+ group of preterm born children with NC-group no significant 
difference could be detected regardless of the method used (Table 13). 
We calculated predicted left and right renal volume for each individual using the formula 
described by Dinkel156. When we compared measured kidney volume with predicted kidney 
volume the most children < 75% of predicted came from the NC+ group and the right side 
was mainly affected (Table 14). Also when calculating the percentage of total kidney volume 
in relation to predicted volume for each group, the NC+ group reached the lowest percentage 
(NC+:85.2%, NC- 90.2% Control: 97.2 of predicted, p= 0.029 (Kruskal-Wallis test)) (Table 
14).  
 
 
 
 
 
 
  30 
Table12. Results for kidney volume adjusted for BSA and kidney length adjusted for height at 
visit comparing the different groups: Extremely preterm infants born <28 weeks gestational 
age with nephrocalcinosis (NC+) or without nephrocalcinosis during the neonatal period 
(NC-) and full- term controls (Control). 
 Estimated difference (CI  95%) P-value 
Total Kidney volume   
NC+ vs NC- -2.97 (-13.09   +7.14) 0.55 
NC+ vs Control -11.12 (-22.57 +0.31) 0.056 
NC- vs Control -8.15 (-19.4 +3.06) 0.15 
(NC+ NC -) vs Control -9.64 (-19.79   +0.51) 0.062 
Right Kidney volume   
NC+ vs NC- -4.72 (-10.31 +0.86) 0.09 
NC+ vs Control -8.7 (-14.9   -2.5) 0.0068 
NC- vs Control -3.97 (-10.09 +2.13) 0.19 
(NC+ NC -) vs Control -6.34 (-11.83 -0.85) 0.024 
Left Kidney Volume   
NC+ vs NC- 2.23 (-5.25 +9.72) 0.55 
NC+ vs Control -5.16 (-13.47  +3.1) 0.21 
NC- vs Control -7.4 (-15.59  +0.79) 0.07 
(NC+ NC -) vs Control -6.28 (-13.63  +1.07) 0.09 
Total Kidney volume  Girls   
NC+ vs NC- 7.66 (-6.93   + 22.25) 0.28 
NC+ vs Control -14.76 (-29.04   -0.49) 0.04 
NC- vs Control -22.42 (-38.76  -6.08) 0.009 
(NC+ NC -) vs Control -18.59 (-32.09  -5.1) 0.009 
Total Kidney volume  Boys   
NC+ vs NC- -6.83 (-21.88  +8.22) 0.36 
NC+ vs Control -6.7 (-25.29  +11.89) 0.46 
NC- vs Control 0.12 (-15.63  +15.94) 0.98 
(NC+ NC -) vs Control -3.28 (-18-81  +12.24) 0.66 
Right Kidney length   
NC+ vs NC- -0.22 (-0.55  +0.1) 0.17 
NC+ vs Control -0.64 (-1.02   -0.26) 0.001 
NC- vs Control -0.42 (-0.78   -0.06) 0.023 
(NC+ NC -) vs Control -0.53 (-0.86   -0.20) 0.002 
Left Kidney Length   
NC+ vs NC- 0.22 (-0.19   +0.64) 0.29 
NC+ vs Control -0.03 (-0.52  +0.44) 0.88 
NC- vs Control -0.25 (-0.72  +0.21) 0.27 
(NC+ NC -) vs Control -0.14 (-0.57   +0.27) 0.49 
Results from the ANCOVA analysis models and planned comparisons. 
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Table 13. Results for Kidney volumes using BSA related KV (KV/BSA) for the different groups: 
Extremely preterm infants born <28 weeks gestational age with nephrocalcinosis (NC+) or 
without nephrocalcinosis during the neonatal period (NC-) and full-term controls (Control). 
 Estimated difference (CI  95%) P-value 
Total Kidney volume  (KV/BSA)   
NC+ vs NC- -4.21 (-15.29   +6.86) 0.44 
NC+ vs Control -14.02 (-25.37  -2.66) 0.016 
NC- vs Control -9.8 (-20.88  +1.27) 0.08 
(NC+ NC -) vs Control -11.8 (-21.51   -2.09) 0.018 
Right Kidney volume (KV/BSA)   
NC+ vs NC- -5.04 (- 11.0   +0.93) 0.09 
NC+ vs Control -9.21  (-15.33  -3.08) 0.003 
NC- vs Control -4.16 (-10.22   +1.89) 0.17 
(NC+ NC -) vs Control -6.62 (-12.01   -1.23) 0.016 
Left Kidney Volume (KV/BSA)   
NC+ vs NC- -2.4 (-10.9    +5.96) 0.55 
NC+ vs Control -6.99  (-15.64   +1.64) 0.11 
NC- vs Control -9.47 (- 18.01   -0.92) 0.03 
(NC+ NC -) vs Control -8.26 (-15.7   -0.82) 0.03 
Results from the ANCOVA analysis models and planned comparisons 
 
 
Table 14. Results for kidney volume in numbers and percentage from predicted volume for the 
different groups: Extremely preterm infants born <28 weeks gestational age with 
nephrocalcinosis (NC+) or without nephrocalcinosis during the neonatal period (NC-) and 
ful- term controls (Control). 
 EPT NC+ EPT NC- Control P-
value  
n <75% of predicted total kidney volume 4 3 1 0.21 
n <75% of predicted right kidney volume 9 4 1 0.01 
n <75% of predicted left kidney volume 4 5 1 0.25 
Percent of predicted total kidney volume 
(SD)  
85.2% 
(11.6) 
90.2% 
(16.5) 
97.2 % 
(12.2) 
 0.029  
Differences between number of patients with <75% of predicted kidney volume are calculated with 
Pearson’s Chi-square test. Differences in percentage are analyzed using Kruskal-Wallis test. 
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Kidney Function 
The estimated glomerular filtration rate (eGFR) by using the cystatin-C based CAPA formula 
showed no difference between preterm born children with or without NC (p= 0.11). Both 
preterm groups taken together had significantly lower but normal eGFR compared to controls 
(p=0.036). Plasma creatinine levels were higher in the control group (p=0.003) but still 
normal while cystatin-C values were insignificantly lower in the control group (p=0.22). 
Using the simplified Schwartz formula showed insignificantly higher eGFR values for the 
preterm group (PT means 113 ml/min/1,73m2 (SD 19.9), Controls 104.6 ml/min/1,73m2 (SD 
17.7)). Plasma electrolytes sodium, potassium, phosphate and calcium as well as urea and 
alkaline phosphatase were not different between the three groups. Urinary proteins and 
electrolytes as well as ratios (albumin/creatinine, magnesium/creatinine, calcium /creatinine, 
phosphate/creatinine) were in the normal range for all groups. Urinary phosphate excretion 
was higher in preterm born children without NC (p=0.015). NC+ preterm born children had a 
trend towards higher calcium/creatinine ratio but not reaching significance (p=0.08). 
 
Table 15. Kidney function results for extremely preterm infants born <28 weeks gestational age with 
nephrocalcinosis (NC+) or without nephrocalcinosis during the neonatal period (NC-) and full-term 
controls (Control). 
 
Estimated difference 
(CI  95%) 
P-value 
eGFR Cystatin-C   
NC+ vs NC- -7.05 (-16.85   +2.74) 0.15 
NC+ vs Control -6.29 (-17.01   +4.42) 0.24 
NC- vs Control -13.35 (-23.7   -3.0) 0.012* 
(NC+ NC -) vs Control -10.11 (-0.69  -19.5) 0.035* 
eGFR Creatinine   
NC+ vs NC- -1.92 (-14.7   +10.84) 0.76 
NC+ vs Control -9.8 (-23.25   +3.6) 0.14 
NC- vs Control -7.89 (-20.66   +4.87) 0.22 
(NC+ NC -) vs Control 8.75 (+20.07   -2.5) 0.12 
Albumine/Creatinine   
NC+ vs NC- -0.08 (-1.93   +1.77) 0.93 
NC+ vs Control -1.03 (-2.84   +0.76) 0.25 
NC- vs Control -0.95 (-2.73   +0.81) 0.28 
(NC+ NC -) vs Control +0.9 (+0.51   -2.5) 0.19 
Results from the ANCOVA analysis models and planned comparisons 
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Blood pressure 
Office blood pressure, systolic, diastolic and mean were not different between the three 
groups. Four out of a total of 41 preterm born children had office systolic blood pressure 
above the 90th percentile. Three of these 4 children also had diastolic blood pressure above 
the 90th percentile. All other children had normal blood pressure below the 90th percentile. 
Ambulatory blood pressure measurements were analyzed in 34 preterm born children 
(NC+:14; NC-: 20). In the remaining 7 patients 24h-BP measurements were either not 
possible or had to be discarded because of insufficient quality. Day-to-night decline below 
10% was absent in 9 of 14 patients (64.3%) in the NC+ group and in 8 of 20 (40%) of NC- 
children. Both preterm born groups combined, 50% of the children did nor reduce their blood 
pressure by 10% from day to night. The mean reduction of systolic blood pressure from day 
to night for the NC+ group was -5.8% (SD 2,9) and -5.4% (SD 3.3) for the NC- group. 
 
Table 16. Results for office blood pressure SDS for children born extremely preterm with 
nephrocalcinosis (EPT NC+) and children born extremely preterm without nephrocalcinosis (EPT 
NC-) and healthy children born at term with normal birth weight (control). Presented as means (SD) 
 EPT NC+  
(n= 20) 
EPT NC-  
(n=21) 
Control (n=19) P-
value 
Office BP, systolic SDS O.18 (0.94) -0.07 (0.72) -0.005 (0.72) 0.58 
Office BP, diastolic SDS 0.12 (0.79) 0.02 (0.51) 0.07 (0.57) 0.87 
Results from one-way ANOVA 
 
Table 17. Results for ABPM for children born extremely preterm with nephrocalcinosis (EPT NC+) 
and children born extremely preterm without nephrocalcinosis (EPT NC-) and healthy children born 
at term with normal birth weight (control) (presented as numbers for percentiles) for the three groups 
 EPT NC+ 
(n=14) 
EPT NC- 
(n=20) 
P -value 
24h ABPM systolic percentile 
<50th  
50-75th 
75-90th  
> 90th 
 
9 
5 
0 
0 
 
14 
3 
3 
0 
 
0.7 
0.2 
0.1 
24h ABPM diastolic percentile 
<50th  
50-75th 
75-90th  
> 90th 
 
13 
1 
0 
0 
 
17 
2 
1 
0 
 
0.5 
0.7 
0.4 
Day-to-night decrease < 10% 
Patients, n (%) 
 
9 (64.3%) 
 
8 (40%) 
 
0.16 
Differences between NC+ and NC- group analyzed with Pearson’s Chi-square test, the normal 
percentiles are taken from reference 87 
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6 DISCUSSION 
The presented studies were designed to identify morphological and functional alterations in 
school children allowing associations between prematurity or SGA and the pathological 
development towards cardiovascular, renal and metabolic diseases. 
Kidney volume 
Using different calculations and adjustment, we found evidence and trends for smaller 
kidneys in school aged children born preterm but no significant difference for SGA born 
children compared to controls (study IV+I respectively). Our findings are in line with the few 
comparable previous studies showing an effect of prematurity on kidney volume or size in 
this age group 112,164-166. Others showed a relation between birth weight and kidney volume 
during the neonatal period and in infancy or later in young adulthood167-169. Several post 
mortem studies have confirmed these findings66,67,170.  
Kidneys were smaller in study IV when children, born extremely preterm had a mean age of 
7.7 years but the difference in kidney volume was more discrete in study I where children 
were almost five years older. This could either indicate that study I was not powered well 
enough to prove the difference or that the selection of exclusively extreme preterm (< 28w 
GA) born children in study IV compared to the less premature born children (<32w GA) in 
study I explained the difference. It is also possible that the kidneys have caught up on growth 
between 7.7 and 12.5 years of age, potentially by hypertrophy with however the same number 
of nephrons. It has previously been shown that kidneys in children or adults born premature 
or SGA have fewer but larger glomeruli due to hyperperfusion of the remaining nephrons 
followed by compensatory enlargement of the filtration surface for the individual glomerulus 
leading to glomeruli hypertrophy 72,73,167,170,171. As the glomeruli constitute a large amount of 
the kidney volume hypertrophy consequently leads to larger kidney volume172. 
Since we wanted to be able to discriminate between LBW due to prematurity or due to IUGR 
in the first cohort and even though the mean KV for the SGA group was almost as low as for 
the PT-group the difference to the control group was not significant. Schmidt et al. followed 
infants and toddlers and found significantly smaller kidney volumes for children born SGA 
not even showing a catch-up growth during the 18 months follow up in their study173. Much 
earlier Hinchliffe et al. could show in an autopsy study that IUGR stillbirth had significant 
reduction in nephron number compared to non-IUGR infants174. It is possible that our study 
was underpowered to prove a significant difference between SGA and control kidney 
volume.  
Looking at gender differences we found that EPT born girls had significantly smaller kidney 
volumes in comparison to girls in the control group but not boys. A finding which was not 
present in study I. There is conflicting evidence with regards to gender difference for kidney 
volume measured with ultrasound. Dinkel et al. could not see a difference between healthy 
boys and girls born at term while Schmidt et al. in a large longitudinal cohort study in 717 
healthy children found that boys had significant larger kidney volumes than girls at the ages 
0, 3 and 18 month using ultrasound technique156,175. A Korean study investigated kidney 
volume in children using scintigraphy (technicium-99m dimercaptosuccinic acid) could not 
find a difference between boys and girls176. However, in a post mortem histological study 
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Neuengarten et al. showed that kidney weight was greater in men but no difference in 
glomerular number between the sexes was observed. They explained the larger kidneys with 
greater BSA in men177. Also earlier Nyengaard et al. showed a difference in gender with girls 
being disadvantaged in kidney size79. Nevertheless, even if kidney volumes are in general 
lower in girls compared to boys we showed that kidney volume in preterm born girls, 
adjusted for BSA, are significantly lower than in girls born at term with normal birth weight. 
This finding suggests that girls are more vulnerable than boys. Keijzer-Veen et al. 
investigated 51 preterm bon young adults at the age of 20 years and could also show smaller 
kidneys in females born premature in comparison to preterm born males178. 
Besides the gender difference there was also a difference between right and left kidney 
volume in study IV. Mean values for right sided kidney volume was lower than the left sided 
kidney volume. In a mixed effects model the difference between right and left kidney reached 
almost significance for all three groups (p=0.055) implicating that the right kidney is 
independently smaller. These findings are in concurrence with most of the previous studies 
on this subject but often describing discrete and not always significant differences 
156,175,176,178-181. However, we could not detect any difference between the right and left side in 
our first study (Study I). Contradicting to our results are the findings from a recent Dutch 
study who found in young adults born preterm and SGA (<32 weeks of gestation and < -2 
SDS) in about 60% the right kidney to be larger178. More recently a large study using three-
dimensional ultrasound technique confirmed our results and detected significantly smaller 
kidneys on the right side in their population of healthy children between 1 and 12 years of age 
182. This laterality in reduced kidney volume might appear trivial but could be of importance 
when it comes to organ donation as more often the left kidney is donated because of easier 
access and vascular surgery 183. This means that the smaller, right kidney remains with the 
donor which might not be a problem as long as there is no reduced nephron endowment 
primarily. 
In study IV we tested the hypothesis that NC developed in extreme preterm born infants 
during their neonatal period can be used as a surrogate for prolonged kidney injury and 
severity of illness and investigated whether it is related to kidney volume. Especially in 
extreme preterm children where there is incomplete nephrogenesis, postnatally acquired 
kidney injury (AKI) is of great importance for the individual’s future renal health and can be 
regarded as a “second hit” to the potentially deficient and more vulnerable EPT infants 
kidneys184,185. On direct comparison of the two groups (NC+ and NC-) we could not see any 
significant difference with regards to kidney volume. Nevertheless, comparing the two 
groups to controls revealed that the NC+ EPT group was more affected than the NC- group of 
EPT born children (Total KV, Right KV, Right KL, Total BSA/KV, Right BSA/KV) (Tables 
11,12,13). Kist-van Holthe measured kidney length in children born preterm below 32 weeks 
of gestation with and without NC but could not detect a difference between the two either112. 
Another study, following 107 preterm children (63 with PT NC+ and 44 PT NC- Controls) to 
the age of 24 months found reduced kidney length for the PT NC+ up to 12 months in both 
kidneys and up to 24 months on the right sided kidney only in PT NC+ in comparison to the 
controls (PT NC-) 104. Some clinicians propose that the routine ultrasound investigation for 
the presence of NC in EPT infants is unnecessary as they regard NC as transient, self-
resolving, benign and no consequences will arise from the positive finding186. However, there 
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is some evidence that NC has an effect on future kidney function and further the knowledge 
of NC might be relevant to the responsible clinician and possibly avoid or limit the use of 
nephrotoxic drugs as well as initiate adequate follow up for the patient104,112.  
To briefly summarize the finding for kidney volume, we found smaller kidneys in children 
born preterm, mainly in girls and mainly on the right side and we could not detect a 
significant effect of NC on kidney volume. 
Kidney function 
We studied kidney function by using the simplified creatinine based Schwartz formula to 
estimate GFR in study I and in addition the cystatin-C based CAPA formula for study IV. 
When using the Schwartz formula for study I no difference in GFR could be detected among 
the three groups. In study IV four children in the preterm groups and one child from the 
control group had eGFR below 85 ml/min/1.73m2 ,which can be defined as mild renal 
insufficiency187. When we were using the cystatin-C based CAPA formula eGFR was normal 
in all groups. However, there was a significantly lower but still normal eGFR measured with 
the cystatin-c based formula in the group of children born prematurely in comparison to the 
control group (p= 0.036). Cystatin-C has been regarded to be superior to creatinine as a 
filtration marker for GFR assessment because of its independency to body mass188. It has also 
been suggested to combine creatinine and cystatin-C in a composite equation to estimate 
GFR189,190 but mainly in adults and a clear improvement in accuracy has not yet been 
described for children191. When using the Schwartz formula we saw a lower (but normal) 
eGFR in the Control group compared to both preterm groups most likely due to higher 
muscle mass in controls and therefore elevated plasma creatinine levels.  
As kidney volume seem to be smaller in children born preterm than in controls born at term 
and kidney volume can be regarded a proxy for nephron number one would speculate that 
kidney function should be impaired when nephron numbers are low192. However, it has been 
suggested that the reduced total filtration surface is compensated by single glomerular 
hyperfiltration in kidneys with fewer nephrons 73. We might have investigated this high-risk 
group of ex preterm or SGA children too early to detected kidney function impairments but 
soon enough to detect lower kidney volume. Keijzer-Veen showed that kidney function was 
impaired in preterm born SGA children at 19 years of age193. Contradicting to our findings 
are the results from Rodriquez-Soriano et al. who could not see any difference in kidney 
length and volume between preterm and control but a diminished GFR in school age 
children194. Kwinta et al. was showing both, reduced kidney volume as well as increased 
cystatin-C levels164. However, cystatin-C levels were perfectly normal in Kwinta’s study in 
the preterm group and no eGFR was calculated. A more recent study from the same group 
followed up on a cohort of EPT born children at the age of 7 and 11 years and compared 
them to children born at term with birth weight > 2500g. Their results are in line with our 
results showing smaller kidneys, higher but normal cystatin-C values and lower but normal 
GFR in the EPT group165.   
In study IV we identified NC as a potential marker or cause for impaired function but we 
could not detect any difference between preterm born children with or without NC with 
regards to eGFR (Table14). Kist van Holthe showed a higher number of children in the NC+ 
group with mild chronic renal insufficiency but these results were not significantly different 
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to the children born preterm without NC112. Another more recent study could not detect an 
effect of NC on GFR in preterm born children104. Others have tried to correlate neonatal AKI 
to worsened renal function at mean age of 6.6 years but could not detect any significant 
difference in GFR or microalbuminuria at this age184.  
Reflecting on the above discussed evidence, it appears that most studies show trends and 
tendencies towards impaired function but no clear pathology is evident in this age group yet. 
In none of the studies focusing on kidney function we were able to detect significant changes 
or differences for urine proteins or electrolytes or their ratios. In study IV we were expecting 
slightly abnormal electrolyte ratios but as no residual NC was detectable on ultrasound 
investigation it was not surprising that urinary electrolytes were in the normal range and no 
significant difference between the groups was found. Preterm children with NC had higher 
ratio for urinary calcium/creatinine but not reaching significance and still in the normal range 
(p=0.08). Only urinary phosphate was significantly higher in children born preterm without 
NC (p=0.05). The phosphate/creatine ratio was highest in children born preterm without NC 
compared to controls (p=0.015). Kist-van Holthe et al. investigated tubular function in 
preterm born children with and without NC but could not detect any evidence for impaired 
proximal or distal tubular function either112. 
Blood pressure 
Blood pressure measurements were performed in both cohorts but ABPM only for study IV. 
The results of the blood pressure measurements from the first cohort are published separately 
and are not part of this thesis. However, the results showed normal BP in all subjects and no 
significant difference between the groups162. In study IV 4/41 preterm born children and one 
child out of the control group had office systolic blood pressure values above the 90th which 
is defined as “high-normal BP” or pre-hypertension86. Whether this was real “high-normal 
BP” or more likely to be a “white coat effect” was initially uncertain87. Only one child with 
elevated office BP had abnormal BP in the ABPM. The ABPM results were normal for all 
other preterm born and control children according to age, gender and height reference 
percentiles in study IV87. These results are in line with a recent large cohort study showing 
that children born extremely preterm have slightly higher but still normal office blood 
pressure at the age of six years 195. A different study followed very preterm born young adults 
at the age of 20 years and found higher day- time BP in comparison to normal controls196.  
In study IV 16/41 (39%) patients from the preterm groups had neurodevelopmental disorders 
of the autism spectrum disease (ASD) and/or ADHD type which reduced the compliance for 
the ABPM. In seven out of those 16 patients the parents either indicated directly that the 
ABPM would not be tolerated or we had to discard the measurements afterwards because of 
insufficient readings and poor quality.  
The results for the 34 successful ABPM showed that 50% of the EPT born children did not 
decrease their blood pressure from day-to-night in an appropriate way indicating abnormal 
circadian blood pressure regulation. These findings are of great interest as the phenomenon of 
“non-dipping” has previously mainly been described for children or adults with established 
pathologies like primary hypertension, DM, renal pathology (autosomal dominant polycystic 
kidney disease, ADPKD) and overweight or obesity197-199. In adults, non-dipping has been 
associated with worse cardiovascular outcomes, microvascular complications and can be 
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regarded as an indicator for the development of hypertension200,201.Few studies have 
described insufficient day-to-night decline of BP in preterm born children. A study in 41 
preterm born children (26-36 weeks of gestation) at the age of 7 years found in comparison to 
27 healthy controls insufficient night dipping in 73% compared to 41% in the control 
group202. It is rather unclear why the prevalence of non-dipping was so high among healthy 
control children in this study. Another recent and slightly larger study investigate 78 preterm 
born children (27 weeks mean GA) and compared them to 38 healthy term control children at 
the mean age of 6.7 years but could only find 16.7% versus 5.2% non-dippers164. We were 
unfortunately unable to perform ABPM in our control group and used published reference 
data for comparison87. However, there is scare information about the prevalence of non-
dippers in healthy term born children. There is also uncertainty with regards to what an 
expected night time decline in BP should be in children and therefore adult criteria had been 
used so far. A slightly older study investigated 61 health children and 40 patients with renal 
diseases between the age of 3 to 6 years with ABPM and found that the healthy children had 
a mean systolic day-to night dip of 8-10% from day systolic blood pressure203. All the 
children investigated in our study were above 6 years of age (mean 7.7years). We therefore 
expected a dip of 10% to be appropriate for our patient group.  
Circadian blood pressure dysregulations in particular a reduced BP drop from day to night 
had been associated with nocturia or nocturnal enuresis in adults and children204,205. This  
symptom was prevalent in 6/17 (35%) of our non-dipping patients, also in 14 (34%) of all 
preterm born children but in none of the controls. In the absence of hypertension, pressure 
diuresis and pressure natriuresis can’t explain nocturnal enuresis in these patients. An 
immaturity or dysfunction of the ANS has been speculated to play a role in those patients 
where other common problems like decreased bladder capacity, bladder over activity, 
increased nocturnal urine production or the inability to wake up cannot explain the condition 
206-208.  
Circadian fluctuations of blood pressure including day-to-night decline are regulated by the 
ANS and the hypothalamo-pituary-adrenal axis209. In study III we were able to show that the 
overall activity of the ANS measured by HRV is significantly diminished in children born 
preterm or SGA. Even though the findings of non-dipping and impaired ANS function 
measured by HRV are not established in the same cohort we felt it was appropriate to create a 
connection between these results.  
Heart rate variability and the autonomic nervous system 
As a reminder, HRV is a measure for the ANS function, illustrating heart-brain interactions 
and ANS dynamics. In the context of the above discussed phenomena of non-dipping and 
circadian regulation of blood pressure these activities would be reflected by the very-low or 
ultra-low frequency spectrum (VLF and ULF) in HRV measurements. The “Low-frequency 
band” confusingly also called “mid-frequency band” is primarily reflecting baroreceptor 
activity at rest. Higher frequencies (HF) reflect parasympathetic or vagal activity often also 
called the “respiratory frequency band” as it reflects much of the variations due to the 
respiratory cycle. The above described finding of “non-dipping” can be related to the findings 
in study III showing low HRV for PT and SGA. The corresponding frequency band for 
circadian regulation (VLF) is significantly lower in PT and SGA groups compared to 
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controls. However, a direct association between low VLF power and “non-dipping” in 
ABPM remains speculative as we do not investigate the same patients. It would have been of 
interest to have both 24-hour Holter ECG and ABPM measurements in the first cohort to be 
able to see if HRV is most affected in the group of children with an insufficient decline in 
day-to-night blood pressure. Nevertheless, even though the VLF power band has traditionally 
“only” been associated with thermoregulation, circadian regulation, hormonal factors 
including renin angiotensin system, it has a stronger association to mortality than LF and HF 
components of power spectrum144,210,211.  There is evidence that disturbances of the ANS 
measured by HRV are visible in children with neurodevelopmental disturbances and autism 
spectrum disease (ASD) in different age groups212-215. In study IV the prevalence of 
neurodevelopmental disorders including ASD was high among children born preterm (16/41, 
39%). However, the HRV results are reflecting on cohort I where the prevalence of 
neurodevelopmental disorders was much lower (6/58, 10%). We could not detect an 
imbalance of the two branches of the ANS on HRV measurements. The so called “autonomic 
balance hypothesis” claims that the parasympathetic and sympathetic systems competitively 
regulate sinoatrial node firing where the increase of one leads to a decrease of the other. It 
seems that the relationship between PNS and SNS is however nonlinear and probably more 
complex216. In view of the non-dipping phenomena in our group of preterm born children the 
LF/HF ratio is not of great interest. As mentioned before circadian dysregulations would 
mainly be reflected in the VLF band or even ultra-low frequency (ULF) power bands. Apart 
from the abnormal circadian regulation leading to the non-dipping phenomenon it is difficult 
to interpret the results from study III. Unlike for the adult population there is limited HRV 
reference data available stratified by age and gender and corrected for confounding factors 
like BMI and blood pressure in children 147,217,218. Some researchers have speculated that a 
sympathetic over activity might be responsible for later development of hypertension and 
cardiovascular complications while others have stated a vagal or parasympathetic withdrawal 
as the pathological mechanism219-223. It is likely that an early environmental effect, whether 
intrauterine or extrauterine, alters the development of the ANS which mainly occurs during 
the third trimester of gestation. A very recent study investigating extremely preterm born 
infants without destructive brain injury at term equivalent and compared HRV parameters to 
normal term controls showed a general depression of HRV in the preterm born group224.  
Insulin resistance and the metabolic syndrome 
Autonomic dysfunction has been observed in patients with type I diabetes mellitus (T1DM) 
and or insulin resistance but also in subjects with overweight and obesity225,226. Cho et al. 
investigated 125 girls aged 8-18 with T1DM and found also a suppression of total, LF and 
HF power and no difference in the LF:HF ratio225. In study II we focus on insulin resistance 
markers in the same cohort investigated for HRV. We found discreet signs for an altered 
glucose handling in children born preterm and those born at term with SGA227. Insulin 
resistance is regarded as a precursor to DM and the MetS and also linked to 
hypertension115,228. A recent study from Taiwan found that changes in the ANS are detectable 
prior to the onset of insulin resistance and the initiation of MetS229. That is a rather relevant 
finding for our study as we can detect altered autonomic function while the markers for 
insulin resistance are still subtle in the group of children born preterm or at term with SGA. 
After adjustments for BMI the group of term SGA children had significantly higher HOMA-
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IR and lower WBISI values in comparison to controls while children born preterm had a 
diminished decrease of IGFBP-1 during OGTT. 
IGFBP-1 has been shown to be a strong predictor for the development of diabetes and can be 
used as a marker for hepatic insulin sensitivity in a test setting using oral or intravenous 
glucose load 230,231. This has already been proven to be valid for children as well232. Non-
obese children born preterm in our cohort showed an attenuated fall of IGFBP-1 following 
glucose provocation which we interpreted as a discrete but significant sign. For the SGA 
group we observed a more peripheral IR which was expressed by higher HOMA-IR, lower 
WBISI and a higher basal insulin during OGTT. This has been shown earlier by Dallar et al. 
but in contrast to our SGA group their SGA children had significantly higher BMI than the 
corresponding controls233. Both our findings are indicating a different glucose handling 
resulting in signs for decreased peripheral insulin sensitivity for the SGA born children and a 
more hepatic insulin resistance type for the preterm born children. It seems that the different 
perinatal exposures like postnatal extrauterine stress and antenatal intrauterine stress have 
different consequences on glucose metabolism. Slightly opposing the above statement, a 
Finnish research group had shown that children born preterm share almost the same risk as 
children born with low birth weight following IUGR for reduced insulin sensitivity234,235 
indicating that the effect of slow fetal growth and short gestation are somehow comparable. 
The same group postulated that the combination of prematurity and SGA doesn't lead to 
“more” insulin resistance. They also suggested that possibly the pre-and postnatal 
pathomechanisms for the SGA and PT respectively, including stress, malnutrition and 
hypoxia, are almost equally leading to the same effect of insulin resistance235,236. A more 
recent and much larger study by Wang et al. showed that plasma insulin levels were inversely 
related to gestational age and thereafter tracking into early childhood indicating impaired 
insulin homeostasis and possible development of insulin resistance. They also speculate that 
the pathomechanisms by which children born preterm or SGA exhibit signs for insulin 
resistance resemble each other237. However, none of the studies distinguished between the 
different types of IR. It seems worrying that these early signs for IR, although discrete, are 
visible in both our groups with pathological perinatal exposure (PT and SGA).  
Insulin resistance is thought to be the central pathomechanism towards the MetS120. It is 
among the aims of this thesis to try to identify markers or components of the MetS for our 
cohorts as the consequences are of utmost importance to these patients. A recent study from 
Denmark followed very preterm born children (<32weeks GA) at the age of 6 years who 
received different post discharge nutritional regimes (breast feeding, formula or fortified 
breast milk) for signs of the MetS. The research group could only see relatively week trends 
and association but no clear evidence for the presence of MetS in patients following a certain 
growth pattern due to formula feeding 238. Others claim to have detected high blood pressure, 
high triglycerides, low HDL and elevated fasting glucose levels suggesting reduced insulin 
sensitivity in VLBW infants born preterm or SGA at the age of 2 years239,240. It is for obvious 
reasons difficult to find all aspects of the MetS at such young age. We were able to detect 
discrete signs for insulin resistance, an affected autonomous nervous system, abnormal 
circadian regulation and smaller kidneys in our target groups with risk factor prematurity or 
SGA. These findings are indicators towards components of the metabolic syndrome. It is of 
great importance to validate and follow up on these indicators in order to enable appropriate 
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timing for intervention and preventive measures. Interventions may lose effectiveness when 
applied too late.  
Much of the research in the DOHaD field has been targeting children or adults born with 
LBW not differentiating between the etiologies for reduced birth weight. This led to the view 
that mainly the fetal period is most vulnerable rather than appreciating that the plastic phase 
of development extends throughout postnatal life in particular for those born preterm. 
Adverse events or development in utero is mainly characterized by malnourishment and 
impaired perfusion and maternal conditions while postnatal adversity might be more 
characterized by stress, pain, suboptimal nutrition, invasive infections and toxic substances in 
form of drugs. We therefore designed our first cohort in a way allowing us to differentiate 
between LBW due to prematurity or due to IUGR. With regards to kidney volume and 
function as well as HRV we could not see a significant difference between PT and SGA 
groups and it seems that intrauterine and extrauterine adverse events and development were 
leading to comparable effects. Only when we were studying markers for insulin resistance we 
detected slightly different clinical phenotypes where preterm born children showed a hepatic 
type of insulin resistance while children born SGA showed peripheral insulin resistance. 
However, it seems that there are only very few clinical outcomes related to either intrauterine 
or extrauterine adverse events and that in general the pathomechanismsn paving the path 
towards cardiovascular or metabolic sequels are not so different236,237,241-243. 
 
6.1 METHODOLOGICAL CONSIDERATIONS 
All four studies presented here are observational, retrospective cohort studies. Out of a 
population of newborns born during a certain time period we retrospectively choose those 
who were born preterm and those who were born term but SGA (Study I-III) and defined 
these conditions as the “risk factor” or “exposure” for an “outcome”. We defined outcome as 
kidney volume, and function, insulin resistance and HRV parameters at school age (Study I-
III). For study IV we added NC as a risk factor to prematurity and had kidney volume, 
function and blood pressure as outcome factors. 
Both selected cohorts are well defined and representative for the population to which we 
intended to generalize the results to. All of the individuals for study I-III, those with the 
exposure and controls, have been recruited from a single hospital where all the patient data 
was stored in similar data systems and all patients had been treated according to the same 
clinical guidelines. This can be regarded as an augmentation in internal validity. However, 
external validity is limited as we have to accept that we do not know how applicable our 
findings are to the risks and effects for children born and cared for at other hospitals 
following different protocols.  
The retrospective design of a cohort study saves time and money in comparison to a 
prospective set up. But equivalent to the “drop outs” in a prospective cohort study the 
retrospective study suffers from the “lost to follow up “problem. The total numbers for both 
our cohorts were rather small. The selection of subjects with an exposure (in our case 
prematurity (all) or SGA (study I-III)) was limited to the children born with this exposure 
during a certain time period at our hospital (1990-1993, 2008-2011). The retrospective design 
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allows for selection bias. It is possible that among those children who were lost to follow up 
or those who declined to participate were children who were sicker or families felt that their 
child already had too many doctors’ visits or would not be willing or able to comply to the 
study protocol. However, we analyzed the perinatal and neonatal characteristics of those non-
participants and couldn’t find a significant difference to the participants. All controls for the 
first cohort were matched for date of birth and gender. For the second cohort matching was 
difficult and we therefore also accepted children volunteering for controls who were slightly 
older (Table 10). 
We have an obvious selection bias in study IV with regards to NC. During the neonatal 
period, it was to the attending consultant’s discretion to decide whether an infant should have 
an ultrasound examination of the kidney to check for NC. It is likely that those infants who 
had been chosen appeared sicker or at higher risk to the clinicians. This also may explain the 
rather high numbers of NC in our cohort (50%) amongst those investigated.  
The outcomes defined in our studies are supposed to be mainly affected by the exposure. We 
tried to restrict the effects of third factors and minimized confounding bias by applying 
inclusion and exclusion criteria as well as adjusting for confounding factors in our analysis. 
The outcome kidney volume and function as well as HRV parameters can be regarded as 
mainly affected by the exposure, namely prematurity and SGA at term. But there is of course 
the chance that these outcomes might have been effected by events during infancy and 
childhood which we haven’t adjusted for. Also, the complex conditions and the complicated 
neonatal course for extreme preterm born children almost invites for interactions or effect 
modifications we could not control for. For example, do we not know if certain medication 
or treatment strategies during the neonatal period had a modifying effect on the ANS leading 
to the depressed activity we measured with HRV. Or if a certain diet under a certain period 
after discharge had an effect on kidney growth or glucose metabolism. 
The additional “exposure” or “risk factor” NC was particularly vulnerable for effect 
modification as there is no absolute certainty about the etiology and pathogenesis of NC. 
However, we screened for hereditary of rare stone promoting diseases and we also reviewed 
all images and results from the neonatal period at the time of visit. It is also uncertain if a 
child screened negative for NC didn't develop signs for NC one or two weeks later. Multiple 
investigations would have minimized this problem. We didn't put too much emphasis on the 
grading of NC for the same reasons as mild NC at screening day could develop to sever NC 
some time later or may have been resolved. Except for the ultrasound investigation for study I 
where the investigator did only know the perinatal exposure of the participants after the 
examination there was no blinding in our studies. 
A further weakness for study I was the fact that we investigate kidney function and kidney 
volume at different times with a few years in-between. It would have been beneficial to 
repeat blood sampling at the second visit when ultrasound investigations of the kidney and 
anthropometrics were performed. 
We also did no distinguish between different ethnicities in our study as numbers were low. It 
is known from earlier research that anthropometrics are different between children from 
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different ethnic background and therefore also linked to organ size and volume which is again 
related to function192. 
Finally, to mention is that we use findings in study III (ANS/HRV) to explain finding in study 
IV (non-dipping). The studies were performed in different cohorts where the exposure is not 
entirely identical as preterm in cohort one were slightly more mature than in cohort two. 
However, we felt that it was appropriate to connect these findings. 
Thanks to the British statistician and epidemiologist Sir Austin Bradford Hill there is a 
guidance using 9 criteria to evaluate hypothesized relationships. We tested one of our 
“effects” kidney volume, using these criteria244,245. 
The cause precedes the effect (Temporality). 
Yes, prematurity or SGA at term preceded the effect of low kidney volume. 
The association should be plausible/the result should be biological sensible 
(Plausibility/Coherence). 
It seems plausible and biological sensible that IUGR or extrauterine growth 
restriction (EUGR) may have an effect on kidney growth and size later in life. 
There should be consistent results from a number of studies (Consistency). 
There are multiple studies available on this topic. 
The association between the cause and the effect should be strong (Strength). 
We see an association but the strength is debatable. 
There should be a dose depended relationship with the effect (Biological gradient). 
Yes, the association is stronger the more preterm the children were born (Study 
I vs IV). 
The exposure causes only one disease (Specificity). 
We can’t state this for our studies. First prematurity doesn’t automatically lead 
to a diseases and secondly prematurity has multiple and different effects. 
Intervention or cessation of exposure should eliminate the effect (Experiment). 
Yes, elimination of prematurity or IUGR should eliminate the fact that children 
later in life can have smaller kidneys. However, kidneys could be smaller 
because of other reasons for example acquired kidney diseases or by ethnicity. 
If one causal agent is known and accepted the likelihood for a second agent to be causal 
is less (Analogy). 
In our case, there is no accepted cause for having smaller kidneys as an ex-
preterm born child. 
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It is important to remind that the studies presented in this thesis are neither designed nor 
powered to assess causality. We are describing associations.  
6.2 ETHICAL CONSIDERATIONS 
The whole field of DOHaD illustrates an ethical dilemma. For generations parents and 
patients have believed that once the neonatal period is overcome with reasonable few scars 
and acceptable development that the chapter can be closed. DOHaD research has shown that 
just by being born too early or being born with significantly lower birth weight than adequate 
for gestational age increases the risk for the development of a variety of serious conditions 
partly addressed in this thesis. This fact illustrates one of the greatest ethical challenges. 
Recruiting families required informing them about why we regarded this research important 
and why we wanted to include their child. By informing them about DOHaD research we 
certainly increased the anxiety level for the family again even though their child might be 
perfectly well of. Most parents were completely unaware about the increased risk for renal, 
metabolic or cardiovascular problems like hypertension or insulin resistance and the risk for 
DM to their children. We initiated more follow up for a few participants as we found some of 
their results worrying and worth checking. In most of these cases the control investigations 
were fine but we worried the families anyhow. The fear we created will stay. But more 
important, the awareness will eventually lead to closer follow up and maybe to a healthier 
lifestyle. At the day of the investigations we always repeated the reasoning behind this 
research project and we always highlighted the importance of lifestyle modifications where 
needed and the enormous risk of overweight and lack of physical activity. However, we also 
mentioned that other factors as for example genetic factors have a huge impact on the 
development of health and disease and that not all adverse development should or could be 
explained by the perinatal exposure. 
For a few mothers and/or fathers it was difficult to come back to the place where some of 
them experienced a lot of pain and suffering. Others on the contrary were excited to meet 
doctors and/or nurses they still remembered from their neonatal period. Some families could 
use the meeting to ask and discuss problems which they had the feeling they couldn’t discuss 
with their community nurses or doctors. 
The examinations included in our studies were apart from line insertion and blood sampling 
not very invasive. An experienced nurse or doctor was responsible for line insertion after 
local anesthesia. The 24-hour Holter ECG as well as the 24-hour blood pressure 
measurements were leading to some discomfort but were overall well tolerated. 
Apart from the ethical impact of this type of research on the patients and their families it 
raises a fundamental challenge to the field of neonatology. DOHaD research has an impact on 
the perspectives for this particular group of patients in terms of outcomes and quality of life. 
It may challenge the field of neonatology with its high speed technical advances and its strive 
to stretch the borders of viability if long term outcomes are worrying and difficult to improve. 
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Also daily practice and management might be associated with ethical competing risks for 
example when decision on nutritional strategies have to be made where one could wish for 
early catch up growth to benefit brain development but maybe to the expense of increasing 
risk for cardiovascular diseases and diabetes in early adulthood or the other way around246.  
Without the DOHaD research neonatologist around the world would most likely have a much 
more limited view on the outcomes of their patients. 
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7 CONCLUSION 
 
Main findings 
• Kidney volume is significantly lower in extremly preterm born children but not in 
very preterm or SGA born children at early school age. 
• Kidney function is normal in all children born preterm or SGA at school age 
• Nephrocalcinosis has no significant effect on renal size or function in children born 
extremely preterm at school age.  
• Office and 24-hour ambulatory blood pressure measurements are normal among 
extremly preterm born children at school age.  
• Circadian blood pressure regulation is affected in extremely preterm born children 
indicating a pre-hypertensive state. 
• Overall HRV is significantly depressed in children born very preterm or SGA 
compared to controls at school age indicating dysfunction of the ANS. 
• Signs for insulin resistance are present in children born preterm or SGA at school age. 
• Preterm born children and children born SGA show comparable effects for HRV and 
kidney function but differ in typ of insulin resistance markers. 
Main message 
Children born very preterm or full-term with LBW have measurable morphological and or 
functional changes already at school age predicting a higher risk for adverse development of 
the cardiovascular, renal and metabolic systems.  
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8 FUTURE PERSPECTIVES 
 
Despite the wide spread accessibility of medical information via social media and the internet 
patients, parents and families know very little about the possible long-term consequences of 
prematurity or IUGR addressed by DOHaD research247. This is unfortunately also true for 
medical professionals. It seems unprofessional if not unethical that we spend an enormous 
amount of work, resources and money on rescuing extremely preterm infants and then neither 
prepare the patients and parents nor the health care professionals involved in this patient 
category with knowledge and tools to limit the potential risk for development of chronic 
diseases. 
So far, the prevention of prematurity hasn’t been very successful. Antenatal and neonatal care 
need to be modified in a way that organogenesis and development is as little affected as 
possible. Aspects of knowledge gained from DOHaD research need to be incorporated into 
neonatal practice. Applying the results from this thesis into daily clinical practice could for 
example implicate that more attention should be given to avoid nephrotoxic drugs and drugs 
with the potential to negatively influence development, to avoid pain and excessive stress, to 
balance nutritional goals for post discharge and prevent excessive catch up and to advise and 
inform parents and care takers early about the detrimental effect of childhood overweight and 
about the need for a healthy life style. Again, preventions and interventions may lose 
effectiveness when applied too late. 
Professional follow up needs to start in early childhood and include the regular control of 
blood pressure, renal function and metabolic status. 
More studies are needed trying to specify the risk groups and discover pathomechanisms 
which would enable treatment as well as evaluating preventive measures. Ideally these 
studies should include more subjects but the value of rather small trials should not be 
underestimated.  
Study IV is part of a larger project where we apart from the nephrological and cardiovascular 
aspect also investigate bone metabolism, growth and nutrition. We will continuously include 
children from the same cohort of extreme preterm born children. We will gather more data on 
kidney volume, function and blood pressure from this cohort and are hoping to publish this 
data soon.  
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9 SVENSK SAMMANFATTNING 
Omkring 10 % av alla barn i världen föds för tidigt, före 37 graviditetsveckor. För tidig födsel 
är huvudanledningen till neonatal dödlighet. 
Förbättringar inom neonatalvården har lett till att allt fler barn överlever till vuxenålder men 
en påverkad organutveckling kan leda till en ökad risk för kroniska sjukdomar senare i livet. 
”Developmental Origins of Health and Disease” är ett nytt forskningsområde om hur 
händelser tidigt i livet kan få effekter senare i livet. 
Denna avhandling omfattar fyra studier om konsekvenser av för tidig födelse eller av låg 
födelsevikt hos barn födda i fullgången tid. 
Den första kohorten bestod av barn undersökta vid 9 och 12 års ålder, och som var födda för 
tidigt (före 32 veckor), födda i fullgången tid med mycket låg födelsevikt (SGA) eller födda i 
fullgången tid med normal födelsevikt (delarbete I-III). Förutom mätningar av njurvolym/-
funktion och markörer för insulinresistens, bedömdes det autonoma nervsystemet med hjälp 
av hjärtfrekvens-variabilitet. 
Den andra kohorten utgjordes av barn som föddes extremt för tidigt (före 28 veckor) mellan 
2008 och 2011 och var i genomsnitt 7 år gamla vid undersökningen (delarbete IV). Som i 
delarbete I undersöktes njurvolym/-funktion. Gruppen av extremt för tidigt födda barn 
delades upp beroende på om de hade haft njurförkalkningar under neonatalperioden 
(nefrokalcinos) och friska fullgångna barn var kontrollgrupp. Vi undersökte också 24 timmars 
blodtryck i denna kohort. 
I skolåldern var njurvolymen lägre bland barn födda för tidigt men skillnaden var enbart 
signifikant i studie IV. Den lägre njurvolymen hade dock ingen mätbar effekt på 
njurfunktionen. Flickor verkade vara mer drabbade av minskad njurvolym än pojkar. Den 
högre njuren var mindre än den vänstra hos extremt för tidigt födda barn men samma mönster 
sågs i alla grupper, även kontrollgruppen (ej signifikant). 
I delarbete II hittade vi diskreta men signifikanta tecken på insulinresistens bland barn födda 
för tidigt och bland barn var födda fullgångna med låg födelsevikt (SGA). De två grupperna 
skilde sig dock: barn födda för tidigt hade en insulinresistens på central nivå (levern) medan 
barn som föddes SGA hade en mer perifer typ av insulinresistens (som muskelvävnad). 
Båda grupperna, barn födda för tidigt och barn födda fullgångna med låg födelsevikt (SGA), 
hade en tydligt minskad hjärtevariabilitet som kan tolkas som en avvikande aktivitet i det 
autonoma nervsystemet (studie III). Vid 24 timmars blodtrycksmätning uppvisade drygt 
hälften inte den normala sänkningen av blodtryck från dag till natt (studie IV). 
Blodtrycksvärdena var i övrigt inte annorlunda mellan grupperna och befann sig 
huvudsakligen i normalområden. 
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Sammanfattningsvis uppvisar skolbarn med låg födelsevikt (för tidigt födda eller fullgångna 
med låg födelsevikt) strukturella och funktionella organförändringar som kan vara indikatorer 
för högt blodtryck, diabetes mellitus typ 2 och njurpåverkan senare i livet. 
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